

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number  
**WO 2004/042062 A1**

(51) International Patent Classification<sup>7</sup>: C12N 15/11

(74) Agent: DARAE PATENT FIRM; 10th Floor, KIPS,  
647-9, Yeoksam-dong, Kangnam-ku, 135-980 Seoul (KR).

(21) International Application Number:  
PCT/KR2003/002339

(22) International Filing Date:  
4 November 2003 (04.11.2003)

(25) Filing Language: Korean

(26) Publication Language: English

(30) Priority Data:  
10-2002-0067856  
4 November 2002 (04.11.2002) KR  
10-2003-0077256  
3 November 2003 (03.11.2003) KR

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,  
SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,  
US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


(71) Applicant (*for all designated States except US*): CHO-A  
PHARM CO., LTD. [KR/KR]; 1st Floor, Acetechno  
Tower, 55-7, Moonrae-dong 3-ga, Yeongdeungpo-ku,  
150-835 Seoul (KR).

Published:  
— with international search report

(71) Applicant and  
(72) Inventor: KIM, Jin-Hol [KR/KR]; 102-803, Chunggu  
Apartment, Chojeon-dong, Jinju-city, 660-360  
Kyeongsangnam-do (KR).

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: PORCINE UROPLAKIN II PROMOTER AND THE PRODUCTION METHOD OF USEFUL PROTEINS USING  
SAID PROMOTER



Porcine UPII promoter : 8847kb

(57) Abstract: The present invention relates to a porcine uroplakin II gene promoter, an expression vector containing the promoter, and a method for producing useful proteins using the vector. The promoter of the present invention promotes the bladder-specific expression of a target protein at high efficiency. An animal, which was transformed using the inventive promoter so as to express the target protein, secretes the target protein in its urine at high concentration, and the protein thus produced shows a superior physiological activity to that of the same kind of the existing protein. As a result, the inventive promoter, the expression vector and transgenic animal using the promoter, can be advantageously used in the production field of useful proteins that are medicinally valuable.

**PORCINE UROPLAKIN II PROMOTER AND THE PRODUCTION  
METHOD OF USEFUL PROTEINS USING SAID PROMOTER**

**Technical Field**

5           The present invention relates to a porcine uroplakin II gene promoter and a method for producing useful proteins using the same.

**Background Art**

10           In the medicinal field, as a method for maximizing the production of proteins such as EPO with high economic-value-added, a mass production method using cell culture technology has been mainly used. However, in this method, production cost is increased due to the use of animal blood as a culture medium, and expert knowledge is required for culture. Furthermore, since it is impossible to completely isolate a freshly produced EPO from an animal EPO contained in the culture medium,  
15           there is a problem in that a finally produced EPO has low purity and activity.

          On the other hand, in a method for producing useful proteins using transgenic animals, a target protein is contained in body fluids secreted by the animals, so that a target protein is easily isolated and purified and maintains superior activity as compared to the existing cell-culture technology. For this reason, an  
20           interest in this method is being rapidly increased.

          In the transgenic animal technology developed till now, mammary gland known to show high protein expression was mainly used as an organ for producing a target protein. However, the results of animal tests showed that it is ultimately impossible to produce several important target proteins, such as EPO, by expression  
25           in milk, due to expression in other tissues as well as the mammary gland.

Furthermore, since various proteins such as albumin are originally contained in milk at large amounts, the resulting target proteins are difficult to purify.

In an attempt to overcome such problems, a method for producing useful proteins using the bladder is recently proposed.

5       The bladder produces urine throughout animal's life regardless of the age and sex of animals, and the urine contains protein and fatty components at only a very small amount of 5-25 mg/l. Thus, the use of the bladder makes the isolation and purification of target proteins significantly easy.

10       However, the protein production efficiency of animals transformed with bladder-specific promoters developed up to now is still at a very low level.

Thus, there is an urgent need for the development of a promoter, which promotes the expression of a target protein at high efficiency.

#### Disclosure of Invention

15       Accordingly, it is an object of the present invention to isolate a porcine uroplakin II gene promoter, which promotes the bladder-specific expression of a target protein, and also to provide a method capable of producing useful proteins at large amounts using this promoter.

20       In one embodiment, the present invention provides a porcine uroplakin II gene promoter.

The porcine uroplakin II promoter preferably has a base sequence of SEQ ID NO: 1:

[SEQ ID NO: 1]:

25       gggctaggagtggaatcagagctggcctatgccacagcaacgcagaatccaaaccacatctccgacctaca  
ccagaccgtcaccataacacaggatccttaaccactgagcaaggctcaggatcaaaccctcatggatactagt

cgggttcttaacccgctgagccacagtgggcactcctgttttgttgtgtcttcgttttggctgcatctgcagcatacagaa  
gttcctgggttaaggaltgaacccaigccacagcagcaacccgagccacagcagtgacaacagcctgatccttaactgct  
agaccaccagggaacgccccctcaacttttcatgccttggaacccctgagtcagtacaacctgacaatnntttttttttt  
tttttgccttttctagggccacttcccggcatgtggagattcgcaggctanaggctaatcgagctgtagccaccggc  
5 ctacaccagagccatagcaacgagggatccgagccgagctcgaacctacactacagctcatggcaacaccggatcgtt  
aaccactgagcaaggccaggggatcgaacccgaacctcatggttcctagtcagattcgtiaaccactgcacatgaca  
ggaactcccaacctgacaattttatcatttctgcaccctagtgttgtagtaattgaaaaattcccaagatgcaaggtcagtgt  
gatggtaattttatgtgtcaacctgactagggcatgttggccggatgtggagtcattgttattctggatgttactgtgaagatat  
gttttgatgaaattaacatttaaatcagtggggggaaaaaagaagtctcgttctggtgcatcagaaacaaatccgacta  
10 ggaaacaagcgggtgcagggttcgatccctggcctcacttagtgagtcaggatctggcgttggcgtgagctgtgttacag  
gtggcagatgcagctcgatctagcattgtgtggtgtggtgtaggccagcagctgtagctctgattaaacccaagtct  
gggaacctccatagccgtgggtgtggccgaaaaagcaaaaaataaataaataaataaatttaaacaggggattttgag  
caaagcagattacccataataggggtgggtctcatcaagttcattgtaggccctagtggaaacaagaccgacctccacctt  
ctcccatgagaaggaaagaattctgccaaaagaccgccttnggacntaaactgcaactcttctctgagttccagcatgtt  
15 ggctcccccatcagactttggacttgccaagcctccgcaattgcatgagccaattccttaaaataaatccgtctatataac  
acatcctgttggttctgtttctccagagaacctgactaacgcagctcgcacctgaagaccagtggccccacactcagc  
tgggtgtcacctccaaacactcagccttctcaaggctcttctagctgtgtcctctctcccccacacagctgttcaaactc  
tcacctcttcagggcgaatcccttctcctcctgagtttctacttccagagaaagcagagaccttcaggagtgtgct  
gccttaacttacttcttcatccctcagccttgcaaaagtataagctttctctgcaccactgccccatttctctctgcagacag  
20 ggtcattcctaaagccaaacgctaatagcctccacctctgatctgagtcctatcttttccctcctccagaagcttctcataaatt  
ctaccccttttcttcttatttctttgaaaacaaaatggaagacagccttcccgttgggtgcagcggaaacagtgggtg  
ccttgaagcgctgggacgcaggttcgaccttggccagcatagtggttaaggatccagtgttgcacagtttggctt  
agattgaaactgcagctcagatctgttccctggcctgggaactcatagccacaggacggccaaaaaagaaaaaagaaag  
aaaaataaaaaacaaaacagaaaagccittctgtaccccaattccctccagttatctctcttcttcccttccagccaag  
25 ctctgcaaagagcgggtctgcacagttctaactctacctcctcccagttggccctggactttctcagcttggttctacccccct

cacccgtaggaaatctgctctgaaggacacgcacccctcacgaccttggcccaggacattttgtaccagcctttcaatc  
ctgaccttcataatcatccgacacctcctttgtgaaacctccaatccactttctcctgttccctcctaagaccattccgcctt  
cttcagccccctccctccatctgtcctttagatgccgacatttcctagatcctgtcctgcgcggncctgtccttccctccaca  
ctctctcaaggactttttccatgtgcgattttgccatggcccaccttccctctttaccagactttccccgggtgctcc  
5 agactcatagactcaattatgaaaacatagttttcatctgatttgcccaagataattgcattagtattactgtataacagcttacc  
ccccaattagtggttataaaataaacacttattctgagaatcagaacctaggcaggacatagttgggtctcatgaagtt  
gcactgaaaatgtccccctgggctaatacataggaggactgaccagggtggaggatctgtccaagctcattcattcaca  
tgccgtaggttgagacagctcttctgtgacttggcaggagcctcaattcctgtcacgtggacctccccctggagggg  
gtcccatgtcctccatggtgagtaatccatgagagcaaggtggaagtgccatgccattaggacctagcctcaggaggg  
10 acctagtcacttctgttagtctgttggccacacagactaacctgacacaatgcacccatccatgacctgtgccagtc  
cattctccacactgtttccagaatgataattacataagtaaaactcctcaaaggcttttgagattttttccattatagttgattta  
taacctcagaggcttttcttctcagcataaaaaccaagttccttaacatagcatgtaaccactggccaccctgccagtgc  
gctagaactctcaccatgtccatccttgaatactgcttctagccaagagctattgttgcagttccagaatgtgtcgggata  
actcacatctctgagccttttcatgtgtgttccctcactttggaatatcccttccatttaggaaggctaattgtccattcatttc  
15 caaaactcagaagcaaatttttttttttttttttttttttggcttttagggccgaactctcagcatatggagggtcccagggtta  
gccatcaaattggaattgtagctgtggcctacaccacagccatagcaacaccagacccaagtcacatctgcaacctacat  
cacagatcatggcaactggtacctaaccactgagtgagcccagggatcaaacacaaattctcatggatactgccag  
gttcattaccactgagccacaacaggaactcctctccttttatggtcacacctgcagcatatggaagttcctgggccaggg  
attgaatctgagtgagctgtgacaatgccgtatcctttaattcactgtgtgggctgaggggntaaantgcccctcctaa  
20 aaaacctgagctgtgcagttggattcttaatccactgcaccacaagggggaaggtcaagaactgtcttgccatctctgtat  
cttatcacctagcatagtagccacatagagaagttgctcaacaaatgttactgaatgaataaatgcatgagctggagttcc  
cattgcggctcagcagtaacaaacctgactagcattcataagaactgggttcgatccctagcctcagtggttaaggatgc  
agcattgctgtgagctgtggtgtaggtgcagacgacactcagatccacattgtgtcactgtggcgcaggccggcctct  
gtagctctgattcgaactcctagcctgggaacgtccatagccacaggtgaggccctaaaaagaaataaataagcaagcaa  
25 gtaagcaagcaggcagtttcttggtgccttgtacccctgtggcctgtgtggtatacaagtaacagctgatccatgtctcagtc

atgtttccccctcagactacctttccgtgccccatctctcccttgacataattggaaaaacaaattcagaattttgtcccactacc  
ttcttgctagctctgtggccttgggaaagctatttattgcctctgagcctctaatttcatctgcaccaaggattaataaaaagg  
agaggataagatgaattacttatattaatttattgaaccagatactgtgctaggcactcttaataaattagcttgagtata  
gtcatagtatcctggtagacagatttttttccctttatggttgacgtgcaacatatggaagtcctgggctggggtcgaat  
5 tggagctgcaggtgcttgcctatgccacagccatggcaacatcatatacaaacccgacctgtgacctacaccacagattgc  
agcaacgctggatccttccccaaggagcaaggccaggaatcaaatgtgatccctcacaacactatgtccggttttaac  
ccgctgagccacaccaggaactccatggcgagacagattttatactctgtctacagaaggagaaagtgaagctcagaatg  
gttaggtaggttaactggccaagatcaaaaaattcaaagaagatttggggcaagtggatcatggcagcattagaaaa  
aataaagaagcatccactgttttcaacactgaacaactgagatttttactctcacagctttttccagcttcataccaagga  
10 cagacgctctgcccatttcccatcagaccaatatttgcctgaacactgcacctttacttttaggtccaagtcaccaggggtttcc  
cagtttgctctacagattctgacactatctccacattttttgacatttttttaagcatttttatactgtcataccttgctaga  
taattgggaagggaatgaatcttccatttataggtgagaaaattgaggttcaagtgactcaccaaaagtcatatagcatca  
ctctcaacaggaggacagcagctcccaccagagggttaacatgtccatggagcctagtggacacatttttcaactgactg  
ggaagcagcagagtggtattgtgaagggggaatcataggtatacaaacagacttaggttctgatccgagctatttctgcttg  
15 caaacaaccatagttcaatttaaaaaaaaaaagaagaaagaaagaaaggaaggagcccccacctcgtgagtgaggaa  
acaaattcaactaggaactgtgaggttgggttcgatccctggccttgctcagtggttaaggatctggcgttgccatgag  
ccgtggtgtaggtgcagactcaactcagatctggcgttgctgtgactgtggctgtgatgtaggctggcagctgtaactccg  
gttagacccagcctgggaacctccatatgcaacctccatatgcggtgggtgtggccctaaaaagaaaaaaaaaaaaa  
aagaggaattcccttatggctcagcaggttaaggatctggtattgtcactgtgtggctctagttagccatagtgaggtt  
20 caatccctggcccaggaacgtctgcatcccacaggtgtggccaaaaaagaagaaaggaaggagttctgttggtgcaca  
ataggattggcaacatcttaggagtactgggacacaggttcaatccctggcccagcacagtggttaaggagccagtggtg  
ctggtcaaaaaagaaagaaaaagtaccatagttagagttaaactgttttaggagctattctttggggcagaacagagagat  
caggagctccttgagagcagaaacttacctttacatccctcgtgcctagcacggttctaggggcatacctggtatttaataaa  
tatagccaactggataggggattggaaggaaaagcagggggagggaacttgagtgagtgaaaaattgagaatccaaa  
25 ggggagacagcctagaaagagtaggtccaagaaagagatcccaggcatttggccctggttcccttttccaagccatg

aggaaatcctcagaggaacagagtgtgtggctttaaatacttcagcgttgtcaatgaatctgctggctaaaaagagttat  
cctcttgctccttcgttgtcctccccctcctcagctcccaaaccttctcggctgctgtgatgggataattagatgcgag  
agctcagcacagatgatgctccagttgcctagcaactaatggttccatggagaccgaaagcacagcctccagagcag  
ccagtgagcagctcggcaggcagggaagacgcaactcagctcctcagaaacctggggagggccaggagtg  
5 gggagaagggggggaatcggagggttaaaggcacaggccctcttatccctctaaatctggtcagagctctgccctc  
ccctccctactctgtcccactcataattcagatggagttgggggcttaggagtgagcccaacacaacctaccctgcaata  
aaccacacttcttctgcttctggttggctgaaaatgnaaaagaaatctcccaagtgaagttaaacancntcctg  
ggttgcaatgggatctgaagagtactaagatccctcagacctggaattccacattagcttctcctctcctcctcctcctc  
aatgtgaaaagatcctcttctcagttgcagagcaatgataggatcttctaaaaggagacaaaagccaaggtgcaggaaaa  
10 atagaattcagttcttcacccaaggcagcctgtcctgggagacaggggtgaaacacttggctctgatctccatcagaggaa  
tccagagtgtgtgtgttggctggggagggggacacaataatagagcatctggtgactcaaagtatgtcctccagagt  
agcatcaatcaatgttacctggaagctgttagaaatgcagaattcaggcttcacctcagaccactgaatcagaaactgc  
atcttaacaagatccctcatgattcatagcacattaaattggagaagcgtgacctgagaccctcctcctctctgcttggg  
cccatagttctaccttattgtcacctcgtctcacctcgtgctcataccccaggctttgagcctaccctcccccatggggaa  
15 aggcacaaaggccaccagccctcacttccctaccaggacctggccctcctctgggactggagaaggacaaagagga  
ccccctctgtggaggtctacgacctcctgaccaagtagtccactaccacaagtggctctacctctctgagtctcagttc  
cacatccacaaaagggtggcaatgctaictgccaccagaatggctgtgagggtggagcaggcaagcctctgtgccat  
cagagaaatgtgtctcttttcttttctccagtggttcttctcgtcttattcttttttttttctgtctgttatttttag  
ggccgtgcctgtggcataggaagtccagggtagggtccaatgggagctgtagccccgggctacgccacagcca  
20 cagcaatgtgggatctgagccacgtctgcaacctacccacagctcacggcaacaccagatccttaaccactgagcaa  
ggccagggatcgagccacgtcctcatggatgctagttgggttcgttaaccgctgagccatgatgataactcctcttctatt  
cttagtcacaaacagtcaacaaagggtgctgaccaaggctgatcgtgccacccccagccccagactgggccagt  
ggccaccccttgggtctcttgaaaactcgtccagcatcaattggctccactctccaggaggatgggaagccctgtggc  
ccctgggactcacaccctctgcatctccagagtgcaggacctggtcttcaggagacaccaagaactggctccccgg  
25 ctctgtgccccccccctactaccagttctctccattcctgcccagtcaggccccctggggttactctcctctctctgt

acaccagtgaacctcagaacctgctccctcctgggaacacccactaccacgtgggagaaggggtcgtctaggggttg  
ggccccagatacacttgaagcaggaacacacgagcccttacatgtgggtgtcccgaagaaggggtttccaccccc  
cgcttagtcaccctgccctctgcagctgcctgagccaccaagaccagccaaggtctcctgccttctggcctgagggc  
cagctccccatcctgaaaaacctgtctggggcctccctgaggctgtagggccaaggcctccctgaggctgtaggg  
5 cccaaggggcaggtgaacaggattccctctggccctcctaccccaggacaaaaccagagccccaggacagggc  
ctcacttgcctcaggaaaccacagctgccagcaccagcccagcaccagcccagct

Moreover, the porcine uroplakin II promoter of the present invention may be one selected from functional equivalents which have one or more disruption, deletion, insertion, point, substitution, nonsense, misense, polymorphism or rearrangement  
10 mutation occurred in the base sequence of SEQ ID NO: 1.

In another embodiment, the present invention provides an expression vector containing all or parts of the promoter.

The expression vector of the present invention preferably contains the promoter and also a base sequence coding for a target protein at the 3'-end of the  
15 promoter.

In another embodiment, the present invention provides an animal transformed with a fertilized ovum into which the expression vector was introduced.

In still another embodiment, the present invention provides a method for the mass production of useful proteins, which comprises collecting urine from the  
20 transgenic animal, and isolating and purifying the target proteins expressed in the urine.

The promoter of the present invention is located at the 5'-end of a porcine uroplakin II gene and regulates the expression of the porcine uroplakin II gene.

The promoter of the present invention can be isolated by screening a porcine  
25 genomic library in the following manner.



In order to obtain parts of the base sequence of the porcine uroplakin II gene to be used as a screening probe, the uroplakin II base sequences of other animals with known base sequences are compared to each other and a primer set (forward primer: SEQ ID NO: 2, and reverse primer: SEQ ID NO: 3) is constructed with reference to portions that are well conserved between the species. Then, RT-PCR is performed with the primer set, using the total RNA of the porcine bladder as a template.

After parts of the uroplakin II fragment are obtained through the RT-PCR reaction, a porcine genomic library is screened using the obtained parts as probes. As shown in FIG. 2, the probes used in the present invention are two probes consisting of probe A containing a portion of exons 2-5 of the uroplakin II gene, and probe B containing a portion of exons 1-2 of the uroplakin II gene.

As shown in FIG. 2, the library screening gives clones containing the uroplakin II gene or promoter. The base sequence of the promoter is finally determined by the comparison between the base sequences of the clones, thereby obtaining the complete base sequence of the porcine uroplakin II promoter.

The promoter thus obtained has a total size of 8847 bp, shows high G + C content, a characteristic of a housekeeping gene, in its base sequence, and contains various Sp1 elements, including AP2 and GATA boxes.

The promoter of the present invention specifically expresses a target protein only in bladder tissue among various porcine tissues. In the case of the porcine uroplakin II gene, it is expressed at 8-14% of total bladder cells, and actively propagated, particularly in an urothelial suprabasal cell, and shows high expression level in an umbrella cell being segmented.

Thus, since the promoter of the present invention induces the bladder-

specific expression of protein at high efficiency, the use of the inventive promoter allows the production of an expression vector that expresses a target protein of foreign origin in a bladder-specific manner.

5 In producing the expression vector of the present invention, the inventive promoter is inserted into the existing vector for protein expression, as a basic backbone, and a base sequence coding for a target protein is inserted into the 3'-end of the promoter, thereby producing the inventive expression vector.

The vector, which can be used as a basic backbone in the production of the inventive expression vector, may be a suitable vector selected from general expression vectors, and its examples include pBluescript SK vectors with various  
10 cloning sites, and a retroviral vector, such as pLNCX.

The expression vector of the present invention can express all proteins, which are used as an active ingredient of medical drugs, and examples of such proteins include erythropoietin (EPO), aldosterone, adreno-corticotropin, blood  
15 clotting factors, gonado-tropin, insulin, prolactin, and vasopressin.

If necessary, the expression vector of the present invention may additionally contain regulators, such as another promoter, an enhancer, a selective marker, a untranslated region (5'-UTR), 3'-UTR, a polyadenylation signal, a ribosome-binding sequence, a base sequence that can be inserted into a certain site of genome, and an  
20 intron, at its suitable locations.

The present invention provides expression vector pUP2/hEPO capable of expressing human EPO under the regulation of the porcine uroplakin II promoter (FIG. 3). The expression vector pUP2/hEPO is a preferred example of the expression vectors containing the uroplakin II promoter.

25 In the expression vector pUP2/hEPO of the present invention, a pBluescript

SK(-) vector is used as a basic backbone, and a human EPO-coding gene (Lin F. K. et al, Proc. Natl. Acad. Sci, USA, Cloning and expression of the human erythropoietin gene, 82:7580-7584, 1985; SEQ ID NO: 4) is fused to the 3' end of the inventive uroplakin II promoter. The expression vector pUP2/hEPO was deposited under the accession number KCTC 10352BP on October 17, 2002 with the Korean Collection for Type Cultures (KCTC), Korean Research Institute of Bioscience and Biotechnology.

If necessary, the expression vector pUP2/hEPO of the present invention may additionally contain a neomycin-resistant gene, an insulator, or a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE), such that the establishment of a transgenic cell line can be easily performed, the expression level of a target protein can be maximized and the stability of expression of the target protein can be ensured.

The neomycin-resistant gene is a gene showing resistance to a G418 reagent used in cell line establishment, and can act as an efficient selective marker in the establishment of an animal cell line, which express protein under the regulation of the UPII promoter. The neomycin-resistant gene has a base sequence of SEQ ID NO: 5:

[SEQ ID NO: 5]

gcggccgcgcgcgtcagggtggcacttttcggggaaatgtgcgcggaaccctattgtttatctaaataca  
ttcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaagggaagagtcctgaggcggaa  
agaaccagctgtggaatgtgtcagttagggtgtggaagtccccaggctccccagcaggcagaagtatgcaaagcat  
gcatctcaattagtcagcaaccaggtgtggaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatctc  
aattagtcagcaaccatagtcggccctaaactccgcccatactccgcccagttccgcccattctccgccc  
catggctgactaattttttatgtatgcagaggccgaggccgcctcggcctctgagctattccagaagtagtgaggaggctt

tttggaggcctaggcttttgcaaagatcgaatcaagagacaggatgaggatcgttcgcatgattgaacaagaaggattgca  
cgagggttctccggccgcttgggtggagaggctattcgctatgactgggcacaacagacaatcggtgctctgatgccg  
ccgtgttccggctgtcagcgcagggggcccggttcttttgcagaccgacctgtccggtgccctgaatgaactgcaag  
acgaggcagcgcggctatcgtggctggccacgacgggcgttccttgcgcagctgtgtcgcaggtgtcactgaagcgg  
5 gaagggactggctgctattggcggaagtccggggcaggatcctctcatctcacctgtcctgccgagaaagtatcc  
atcatggctgaigcaatcgggcggctgcatacgttgatccggctacctgcccattcgaccaccaagcgaacatcgcat  
cgagcgagcacgtactcggatggaagccggtcttgcgatcaggatgatctggacgaagagcatcaggggctcgcgcc  
agccgaactgttcgccaggctcaaggcgagcatgcccgcggcgaggatctcgtcgtgacctatggcgatgcctgcttg  
ccgaatatcatggtggaaaatggccgcttttctggattcatcgactgtggccggctgggtgtggcgaccgctatcaggac  
10 atagcgttggctacccgtgatattgctgaagagcttggcggcgaatgggctgaccgcttctctgtgcttacggtatcgccg  
ctcccgaatcgagcgcacgccttctatgccttcttgacgagttctctgagcgggactctgggggtcgaatgaccgac  
caagcgacgcccacctgccatcacgagattcgaattccaccgccgcttctatgaaagggtgggttcggaatcgtttcc  
gggacgccggctggatgatcctccagcgcggggatctcatgctggagtcttcgccaccctagggggaggctaactga  
aacacggaaggagacaataccggaaggaacccgcgctatgacggcaataaaaagacagaataaaacgcacggtgttg  
15 ggtcgtttgtcataaacgcggggtcggctccagggtggcactctgtcgataccccaccgagacccattggggccaa  
tacgcccgcgttcttcttccccacccaccccccaagttcgggtgaagcccagggtcgcagccaacgtcggggc  
ggcaggccctgccatagcctcaggttactcatatatactttagattgatttaaaacttcattttaatttaaaaggatctaggtga  
agatccttttgataatctcatgacaaaatccctaacgtgagtttcttccactgagcgtccgatcg

The insulator is a factor promoting the effect of a regulator adjacent to the  
20 promoter and also promoting position-independent expression, and allows a target  
protein to be stably expressed under the regulation of the UPII promoter. The  
insulator has a base sequence of SEQ ID NO: 6

[SEQ ID NO: 6]:

tcgactctagaggacagcccccccaagccccaggatgaattacgtcctccccgctaggggca  
25 gcagcgagccgggggtccgctccggctccggcgtccccccgcatccccgagccggcagcgtcggggacag

ccccggcacggggaagggtggcacgggaicgcttctctgaacgcttctcgtgctctttgagcctgcagacacctgggg  
ggatcacgggaaaaagctttaggctgaaagagagattagaatgacagaatcatagaacggcctgggttgcaaaggagc  
acagtgtcatccagatccaacccctgctatgtgcagggtcatcaaccagcagcccaggctgccagagccacatcca  
gcctggccttgaatgcctgcagggtggggcatccacagcctcctgggcaacctgttcagtgcgtcaccacctctggg  
5 ggaaaaactgcctcctcatatccaacccaaacctcccctgtctcagtgtaaagccattccccctgtcctatcaagggggag  
tttctgtgacattgttggctgggtgacacatgtttgccaattcagtgcatcacggagaggcagatcttggggataagga  
agtgcaggacagcatggacgtgggacatgcagggtgtgagggtctgggacactctccaagtcacagcgttcagaaca  
gccttaaggataagaagataggatagaaggacaaagagcaagttaaaacccagcatggagaggagcacaaaaaggcc  
acagacactgctggctccctgtgtctgagcctgcatgtttgatgggtgtctggatgcaagcagaaggggtggaagagcttgcc  
10 tggagagatacagctgggtcagtaggactgggacaggcagctggagaattgcatgtatgttcatacaatcgtcaaat  
catgaaggctggaaagcctccaagatcccaagaccaaccccaacccaccaccgtgccactggccatgtccctcagt  
gccacatcccacagttctcatcacctccagggtgacgggtgacccccccacctccgtgggcagctgtgccactgcagcac  
cgtctttggagaaggtaaatcttgctaaatccagcccagccctcccctggcacaacgtaaggccattatctcatccaac  
tccaggacggagtcagtgaggatggggctctagagggtgacagccccccccaaagccccagggtgtaattacgtccc  
15 tccccgctaggggcagcagcgagccgcccggggctccgctccggtccggcgtccccccgcatccccgagccggc  
agcgtgcggggacagcccgggcacggggaagggtggcacgggatcgcttctctgaacgcttctcgtgctctttgagc  
ctgcagacacctggggggatacgggaaaaagctttaggctgaaagagagattagaatgacagaatcatagaacggc  
ctgggttgcaaaggagcacagtgtcatccagatccaacccctgctatgtgcagggtcatcaaccagcagcccaggct  
gccagagccacatccagcctggccttgaatgcctgcagggtggggcatccacagcctcctgggcaacctgttcagt  
20 gcgtcaccacctctggggaaaaactgcctcctcatatccaacccaaacctcccctgtctcagtgtaaagccattccccct  
tgtcctatcaagggggagtttctgtgacatgttggctgggtgacacatgtttgccaattcagtgcatcacggagaggc  
agatcttggggataaggaagtgcaggacagcatggacgtgggacatgcagggtgtgagggtctgggacactctccaa  
gtcacagcgttcagaacagccttaaggataagaagataggatagaaggacaaaagcaagttaaaacccagcatggag  
aggagcacaaaaaggccacagacactgctggctccctgtgtctgagcctgcatgtttgatgggtgtctggatgcaagcagaa  
25 ggggtccatgtccctcagtgccacatcccacagttctcatcacctccagggtgacgggtgacccccccacctccgtgggca

gctgtgccactgcagcaccgctcttggagaaggtaaacttgctaaatccagcccaccctcccctggcacaacgtaag  
gccattatctctcatccaactccaggaacggagtcagttag

The WPRE is a regulator contributing to the stabilization of mRNA so as to increase the synthesis of a target protein, and allows the target protein to be  
5 expressed at large amounts under the regulation of the UPII promoter. The WPRE has a base sequence of SEQ ID NO: 7:

[SEQ ID NO: 7]

accagggttctgttctgttaatcaacctctggattacaaaatttgtgaagattgactggtattcttaactatgttgct  
cctttacgctatgtggatacgtgtcttaatgccttggatcatgctattgcttcccgtatggcttcatttctcctcctgtataa  
10 atcctgggtgctgtctttatgaggagttgtggccggtgtcaggcaacgtggcgtggtgtgactgtgttgctgacgcaa  
ccccactggttggggcattgccaccacctgtcagctccttccgggacttgccttccccctccctattgccacggcgga  
actcatcgccgcctgccttgcctgctggacaggggctcggctgttgggcactgacaattccgtggtgtgtcgggga  
agctgacgtcctttccatggctgtcgcctgtgttgcacctggattctgcgcgggacgtccttctgtacgtcccttcggcc  
ctcaatccagcggaccttcttcccgccgctgtgccggctctgcggccttccgcgtcttcgccttcgcctcagacg  
15 agtcggatctcccttgggccgctccccgctgttgcctcgggctcctcgag

The present invention provides an I/pUP2/hEPO vector, a pUP2/hEPO(WPRE) vector and an I/pUP2/hEPO(WPRE) vector, as preferred examples of the expression vector which additionally contains the regulators.

Such vectors are produced by inserting the neomycin-resistant gene into the  
20 inventive pUP2/hEPO vector, and then either inserting the WPRE into the 3' end of the EPO gene or inserting the insulator into the 5' end of the UPII promoter.

Examples of an animal, which can be transformed with the expression vector of the present invention, include all animals that urinate, such as porcine, mouse, bovine, poultry, ovine and caprine animals.

25 A method for the production of a transgenic animal using the expression

vector of the present invention is conducted according to the conventional method. Namely, a fertilized ovum is collected from a healthy individual among animals to be transformed, and the inventive expression vector is introduced into the fertilized ovum. Then, a pseudopregnant mouse is obtained using a vasectomized mouse, and  
5 the fertilized ovum is implanted into the oviduct of the pseudopregnant mouse as a surrogate mother. Then, transformed individuals among the descendants obtained from the surrogate mother are screened.

Thereafter, urine is collected from the screened individuals confirmed to be transformed, and then a target protein is isolated and purified from the collected urine,  
10 thereby producing useful proteins.

In the inventive method for the production of useful proteins, the isolation and purification processes of urine can be performed by the conventional technique, such as filtration or chromatography.

The inventive transgenic animal produced as described above expresses a  
15 target protein in a bladder-specific manner, and expresses the target protein in urine at a far higher concentration than the existing method.

For example, a mouse transformed with the expression vector pUP2/hEPO of the present invention shows a high EPO expression level of 0.5-1 mg/ml. Although EPO is a protein that is difficult to express since it causes the early death of  
20 an embryo, the inventive animal shows at least 1,000 times higher EPO expression level than the expression level of protein in urine, which is obtained using the existing uroplakin promoter.

Furthermore, the protein produced from the inventive transgenic animal shows a superior physiological activity to that of the same kind of commercially  
25 available protein.

For example, EPO obtained from a mouse transformed with the expression vector pUP2/hEPO of the present invention maintains the survival rate of an EPO-dependent hepatocyte cell line at a higher level than that of commercially available EPO.

5           As a result, the promoter of the present invention, and the expression vector and transgenic animal using the promoter, can be advantageously used in the production field of useful proteins that have been difficult to produce at large amounts.

10 **Brief Description of Drawings**

FIG. 1 shows the structure of probes used in isolating a porcine uroplakin II promoter of the present invention, and clones isolated by the probe;

FIG. 2 shows the structure of expression vector pUP2/hEPO of the present invention:

15            FIG. 3 shows the bladder-specific expression of a porcine uroplakin II mRNA;

FIG. 4 shows the urothelium-specific expression of a porcine uroplakin II protein;

FIG. 5 shows the expression level of a porcine uroplakin II protein in bladder  
20 cells and the umbrella cell-specific expression of this protein;

FIG. 6 shows the bladder-specific expression of EPO mRNA in a mouse transformed with the expression vector pUP2/hEPO of the present invention;

FIG. 7 shows the expression of an EPO protein in a mouse transformed with the expression vector pUP2/hEPO of the present invention;

25 FIG. 8 shows the structure of the expression vector pUP2/hEPO of present



invention;

FIG 9 shows the structure of the expression vector pUP2/hEPO of the present invention;

FIG 10 shows the structure of the expression vector pUP2/hEPO of the present invention;

FIG 11 shows the comparison between the EPO gene expression levels of the inventive expression vectors; and

FIG 12 shows the comparison between the EPO protein expression levels of the inventive expression vectors.

10

### Best Mode for Carrying Out the Invention

The present invention will hereinafter be described in further detail by examples. It should however be borne in mind that the present invention is not limited to or by the examples.

15

#### Example 1: Isolation of inventive porcine uroplakin II promoter

In order to isolate the porcine uroplakin II promoter of the present invention, the following test was performed.

1) Preparation of probe by RT-PCR (Reverse Transcriptase- Polymerase Chain Reaction)

20

Since the base sequence of a porcine uroplakin II gene is not yet known, mouse and bovine uroplakin II cDNAs whose base sequences had been known were compared to each other. With reference to portions that are highly conserved between the two species, a degenerate primer set for use in the amplification of the porcine uroplakin II cDNA was produced. The base sequences of the forward and

25

reverse primers are shown in SEQ ID NOS: 2 and 3, respectively.

Using the primer set, RT reaction was performed on the total RNA of the porcine bladder with a MuMLV reverse transcriptase, and the resulting cDNA was subjected to PCR using a Taq polymerase. The reading of the base sequence of the amplified DNA showed that the amplified DNA is parts of an uroplakin II gene. The amplified DNA was cloned with a pGEM T-easy vector.

In order to produce a probe to be used in the isolation of an uroplakin II promoter, 50 ng of the cloned DNA was boiled for 3 minutes, and cooled in ice to denature it. The denatured DNA was added to a reaction buffer containing primer, dNTP, [ $\alpha$ - $^{32}$ P]dCTP (3000 Ci/nmol, NEN), and then a Klenow fragment was added to the solution and reacted at 37 °C for 1 hour. The probes thus obtained consist of probe A comprising a portion of exons 2-5 of the uroplakin II gene and probe B comprising a portion of exons 1-2 of the uroplakin II gene (FIG 1).

Then, the reaction solution was purified using a Sephadex G-50 column, thereby preparing  $^{32}$ P-labeled DNA probe A and probe B for porcine uroplakin II promoter probing.

## 2) Library Screening

To isolate the porcine uroplakin II promoter, a porcine genomic library was screened. In this example, the porcine genomic library which had been inserted into a lambda Fix II phage vector (Stratagene) was used.

Host bacteria to be introduced with the library were prepared as follows.

5 ml LB medium containing 0.2% maltose was inoculated with one bacteria colony and cultured at 37 °C overnight. 1% of the culture medium was transferred into 50 ml of a fresh LB medium containing 0.2% maltose and cultured for 2.5 hours. When the absorbance at 600 nm reached about 0.5, the culture solution was

centrifuged at 2,500 rpm for 10 minutes. The resulting cell precipitates were suspended in 10 ml of sterilized magnesium sulfate solution to a final concentration of  $1 \times 10^{10}$  cells/ml, and stored at 4 °C until test.

For titration, the library was serially diluted in SM solution at various  
5 concentrations. A plate containing solid LB medium was warmed in a 37 °C incubator, and top agar was dissolved and put in a water bath kept at 48 °C. 10 µl of each of the phage solutions diluted at various concentrations was mixed with 100 µl of the above prepared host bacteria, and the host bacteria were infected with the phage at 37 °C.

10 The host bacteria infected with the phage were added to the top agar, well shaken, and then poured on the above-prepared LB medium. After 15 minutes, the plate was turned upside down and cultured in a 37 °C incubator overnight. On the medium of the plate cultured overnight, plaques indicating that the phage dissolved the host bacteria after reproducing library DNA in the host bacteria were formed, and  
15 for use in a subsequent step, the plate was cooled at 4 °C for at least one hour.

NC filters with serial numbers were provided, and the above-prepared library DNA plate was covered with the filters in such a manner that the middle portion of the filters was first contacted. The filters were pricked with a needle in a vertical direction to the filter so as to mark a position, and one minute later, the filters were  
20 carefully separated from the medium.

Each of the filters was successively immersed in denaturation solution, neutralization solution and 2 X SSC solution for one minute each solution, and then, placed in an oven at 80 °C for 2 hours such that the transferred library DNA was completely immobilized on the filter.

25 Each of the immobilized filters was floated on 2 X SSC solution to wet it,

and then prehybridized in a petri dish containing prehybridization solution with slow shaking at 68 °C for 1 hour. After the prehybridization, each of the filters was added with the probes prepared in the part 1) of Example 1, and hybridized with slow shaking at 68 °C for 18 hours. After the hybridization, the process of immersing  
5 the filters in 2 X SSC solution containing 0.1% SDS and washing the filters with shaking at 65 °C for 10 minutes was repeated two times. After the washing, the filters were dried in air and subjected to autoradiography.

By the comparison between the autoradiographic result and the plate, a plaque showing a positive sign was selected. The plaque was placed in 500 µl SM  
10 buffer solution, and one drop of chloroform was added to and well mixed with the solution, and the mixture was stored at 4 °C. Such a screening process was repeated three times, and clones showing a positive sign were finally obtained. DNA contained in each of the clones was purified using a Qiagen lambda mini kit.

The reading of the DNA base sequence was performed using an ABI 377  
15 DNA sequencer (Applied Biosystem), the results of the sequence reading was processed using a CAP2 sequence assembly system, sequence comparison was performed using BLAST, SMART, PROSITE and the like, and motif analysis was conducted using a Clustal W program.

As a result, when the screening was performed with the probe A, clones A  
20 and B as shown in FIG. 1 were obtained. When the probe B was used in the screening, clones C and D as shown in FIG. 1 were obtained. Since each of such clones contained a porcine uroplakin II promoter or a structural gene at the 3' end, the comparison between the clones provided the complete base sequence of the porcine uroplakin II promoter.

25 The porcine uroplakin II promoter of the present invention has a total size of

8874 bp, and its base sequence is shown in SEQ ID NO: 1.

3) Examination of expression pattern of protein which is expressed under regulation of inventive promoter

In order to examine the expression pattern of a protein, which is expressed under the regulation of the inventive promoter, the expression of porcine uroplakin II was examined as follows.

3-1) Examination of bladder-specific expression of protein which is expressed under regulation of inventive promoter

In order to examine if a protein, which is expressed under the regulation of the inventive promoter, is expressed in a bladder-specific manner, Northern analysis was performed.

The porcine uroplakin II cDNA obtained in the part 2) of Example 1 was used as a probe, and at the same time, a probe for actin which is expressed in all tissues at a constant level was provided as a control group. In order to confirm the expression of the porcine uroplakin II mRNA in various porcine body tissues using the probes, total RNA for tissues including the bladder, the heart, the liver, the lungs, the womb and the spleen was subjected to electrophoresis as follows.

0.7 g of agarose was placed in a 250 ml Erlenmeyer flask, added with 58 ml of distilled water, completely dissolved in an electronic rang, and then cooled in a water bath kept at 60 °C. When the temperature of the agarose gel was adjusted to 60 °C, 7 ml of 10 x running buffer was carefully added with shaking, and 11.9 ml of formaldehyde was further added to prepare 1 × formaldehyde running gel solution. This solution was placed in a preset electrophoretic system and left to stand for about 20 minutes to produce gel.

6 µl RNA, 2.5 µl 10 × running buffer, 4 µl formaldehyde, and 12.5 µl

formamide were well mixed in a microcentrifuge tube, and heated at 65 °C for 5 minutes, and then cooled in ice. 2.5 µl gel-loading buffer was added to and well mixed with the sample, and loaded on gel, which had been pre-electrophoresed at 5 V for about 5 minutes. The resulting substance was electrophoresed in 1 x running  
5 buffer at 120 V/cm. After the electrophoresis, the gel was placed in 0.05 N sodium hydroxide solution for about 10 minutes, so as to partially cut RNA such that an efficiency in a subsequent transfer process is enhanced.

The gel was placed in 0.1 M Tris solution (pH 7.5) for 30 minutes, and in 20 x SSC solution (3M sodium chloride, 0.3M sodium-citrate, pH 7.3) for about 30  
10 minutes, and then DNA was transferred to the gel using a positively charged membrane. For RNA immobilization, the transferred membrane was left to stand at 80 °C for 2 hours.

The membrane was placed in a vinyl bag in which hybridization solution was contained at a minimum volume at which the membrane can be completely  
15 submerged. Next, the bag was stored in a 68 °C shaking incubator for at least one hour. Then, the solution was drawn out, replaced by 15 ml of a hybridization solution containing the probe, and left to stand in 68 °C shaking incubator overnight.

After the hybridization, the membrane was washed with washing solution 1 (2 x SSC, 0.1% SDS) at room temperature for 30 minutes while replacing the  
20 washing solution, and then, washed with washing solution 2 (0.2 x SSC, 0.1% SDS) at 55 °C for 30 minutes while replacing the washing solution 2. After the membrane was completely dried at room temperature, it was subjected to autoradiography to examine if the porcine uroplakin II mRNA was expressed. The results are shown in FIG 3.

25 As shown in FIG. 3a, the actin mRNA as an internal control group was

uniformly expressed in all the tissues. On the other hand, as shown in FIG 3b, the uroplakin II mRNA which is expressed under the regulation of the inventive promoter was specifically expressed only in the porcine bladder (FIG 3b).

As a result, it can be found that the promoter of the present invention  
5 expresses the protein in a bladder-specific manner.

3-2) Examination of urothelium-specific expression of protein which is expressed under the regulation of inventive promoter

Meanwhile, in order to examine if the protein which is expressed under the regulation of the inventive promoter is expressed in any cell of bladder tissue,  
10 immunohistochemical staining was conducted as follows.

A paraffin fragment of porcine bladder tissue was provided, and maintained in Histoclear solution for about 10 minutes to remove paraffin. The fragment was immersed in aqueous alcohol solution at gradually decreasing concentrations to dehydrate it, and then immersed in methanol containing 3% hydrogen peroxide and  
15 0.05 N hydrochloric acid containing 0.1% pepsin, so as to prevent the fragment being nonspecifically stained.

The fragment was washed two times with TBS buffer (0.05 M Tris, pH 7.4, 0.85% sodium chloride) for 5 minutes, and then, subjected to blocking reaction in TBS which had been diluted with normal equine serum at a ratio of 1:5.

20 The blocked fragment was immersed overnight in TBS which had been diluted with a primary antibody at a ratio of 1:500. At this time, a polyclonal antibody which can specifically bind to the porcine uroplakin II protein was used as the primary antibody, and one drop of equine serum of an ABC kit was used as a negative control group.

25 The fragment which had been subjected to the primary antibody reaction was

washed two times with TBS for five minutes each time to remove an excess of the antibody, and then reacted with a biotin-attached secondary antibody for 30 minutes. Thereafter, the fragment was washed three times with TBS for 5 minutes, followed by reaction with an ABC reagent for 30 minutes. The fragment was washed with  
5 TBS again, rinsed with PBS containing 1% Triton-X 100 for 30 seconds, and then reacted with 0.05M Tris buffer (pH 7.6) containing 0.5% diaminobenzidine (DAB) and 0.01% hydrogen peroxide, to develop color.

After the color development reaction, the fragment was washed with water, mounted on an optical microscope, and observed for its developed portions. The  
10 results are shown in FIG. 4.

As shown in FIG. 4a, the control group did not show any positive sign. However, as shown in FIG. 4b, the reaction of the bladder tissue with the antibody to the uroplakin II protein showed that the promoter of the present invention regulated the uroplakin II protein such that the protein is specifically expressed only in the  
15 porcine urothelium, particularly in the cytoplasm of the suprabasal cell.

### 3-3) Examination of expression level of protein which is expressed under regulation of inventive promoter

Since the urothelium cell is known to have lower protein synthesis ability than that of mammary gland where the protein synthesis actively occurs, the actual  
20 expression level of the protein which is expressed under the regulation of the inventive promoter was examined by Laser scanning cytometry (hereinafter, referred to as 'LSC') in the following manner.

Porcine bladder tissue was split finely, added to DMEM/F12 medium (Gibco) containing 1mg/ml collagenase type I (Sigma), 0.51 mg/ml hyaluronidase  
25 (Sigma) and 50µg/ml gentamicin, and subjected to cleavage reaction at 37 °C for 1



hour.

After the resulting substance was washed with PBS, bulky masses were filtered out using a 60  $\mu$ m nylon membrane (Milipore), and the suspended single cells were attached to a Lab-Tek chamber slide (Nunc) coated with 0.1% gelatin.

5 The cells attached to the slide were washed with cold PBS and immobilized in cold methanol for 15 minutes, followed by treatment in 0.1% Triton-X 100 solution for 10 minutes.

The immobilized cells were blocked in 1% BSA-containing PBS solution for one hour and reacted with a 1:100 solution of the uroplakin II polyclonal antibody  
10 prepared in the part 3-2) of Example 1 at room temperature for 2 hours. After washing with PBS, the cells were reacted with a FITC-attached anti-mouse IgG secondary antibody (Cappel Laboratories). At this time, a group reacted with only the secondary antibody was also prepared as a negative control group.

After the cells were washed three times with PBS containing 0.1% Tween-20,  
15 they were stained with 50  $\mu$ g/ml propidium iodide (PI) such that total cell number can be measured. Upon LSC analysis, fluorescent light was emitted with a 488 nm argon laser, fluorescent expression was observed using a 530 nm filter for FITC and a 570 nm filter for PI. The results are shown in FIG. 5. The results of analysis for the negative control group were shown in FIG. 5a, the results for analysis for the cell  
20 expressing the uroplakin II among the bladder cells were shown in FIG. 5b, and the results of analysis for the immune phenotype of the bladder cell expressing the uroplakin II were shown in FIG. 5c.

As shown in FIG. 5b, it was found that about 8-14% of the total bladder cells expressed the uroplakin II. As shown in FIG. 5c, it was found that most of the cells  
25 were umbrella cells being actively propagated and cleaved. Considering that

proteins in urine are generally at a very low level of 5-25 mg/l, the above-mentioned expression level of the uroplakin II is significantly high. Also, it is presumed that the use of bladder tissue allows proteins to be isolated and purified at a higher efficiency than the use of mammary gland tissue.

5           As a result, it can be found that the promoter of the present invention allows a target protein to be expressed in the bladder at excellent efficiency.

Example 2: Production of inventive expression vector pUP2/hEPO

Using the inventive promoter isolated in Example 1, a vector which  
10       expresses EPO under the regulation of this promoter was produced in the following manner.

A pBluescript SK(-) vector was selected as a basic backbone vector and inserted with the inventive promoter isolated in the part 2) of Example 1. Thereafter, a gene coding for human EPO (SEQ ID NO: 4) was inserted in the 3'-end  
15       of the promoter.

The resulting expression vector has a structure as shown in FIG. 2 and will express EPO under the regulation of the uroplakin II promoter of the present invention. This vector was termed "pUP2/hEPO" and deposited under the accession number KCTC 10352BP on October 17, 2002 with the Korean Collection  
20       for Type Cultures (KCTC), Korean Research Institute of Bioscience and Biotechnology.

Example 3: Production of fertilized ovum introduced with inventive expression vector pUP2/hEPO

25           A fertilized ovum introduced with the inventive expression vector

pUP2/hEPO produced in Example 2 was produced as follows.

1) Collection of fertilized ovum

At 3 days before collecting a fertilized ovum, PMSG was administered into the abdominal cavity of a female mouse, and at 5 p.m., after two days, the female  
5 mouse was administered with hCG and then cross-fertilized with a male mouse. In the morning the next day of the cross-fertilization, whether a plug had been produced in the female mouse or not was observed to examine if the female mouse became pregnant.

The mouse that has been confirmed to be pregnant was subjected to cervical  
10 vertebral dislocation, its abdomen open was cut with surgical scissors, and the connective tissue portion of the womb was separated. The portion between the oviduct and the womb was torn with a pincette, after which the portion between the ovary and the oviduct was cut with scissors. Then, the side of the womb in the portion torn with the pincette was cut and the oviduct was separated.

15 The separated oviduct was placed in M2 medium and put on an insulator board to prevent its temperature from being reduced. The oviduct ampulla was broken with a 1 ml needle under a microscope, and an embryo was collected. The collected embryo was placed in hyaluronidase solution that had been exposed to room temperature, and it was left to stand until a cumulus oophorus cell was  
20 detached.

The resulting solution was washed 2-3 times with M2 medium, centrifuged at 13,000 rpm for 5 minutes and washed 2-3 times with M2 medium again, and a normal fertilized ovum was screened. The screened fertilized ovum was washed 2-3 times in M16 medium coated with paraffin oil, and then, it was transferred and  
25 stored in a 37 °C incubator.

## 2) Microinjection of DNA into fertilized ovum

Using a micromanipulator, the expression vector pUP2/hEPO of the present invention was injected into the fertilized ovum collected as described above.

### 5 Example 4: Preparation of transgenic mouse which produces human EPO under regulation of inventive promoter

Using the fertilized ovum produced in Example 3, a transgenic mouse that produces human EPO under the regulation of the inventive promoter was produced in the following manner.

#### 10 1) Preparation of vasectomized mouse

A vasectomized mouse to be used in making a surrogate mother pseudopregnant was prepared as follows.

A six-week-old ICR mouse was selected and anesthetized, and then the integument being about 1.5 cm apart above the pubic bone was incised about 1 cm  
15 along the pubic bone using a pincette and scissors. Standing to the right or left so as to prevent the incision opening being overlapped, the muscularis was incised, and a testicle descended to the scrotum was moved into the abdominal cavity. The testicle, the epididymis and the spermaduct, were separated from each other with a pincette, a membrane around the speraduct was separated with a pincette, and the  
20 spermaduct was cut with a heated pincette. After confirming that the spermaduct had been separated, the muscularis was sutured and the mouse was placed in a warmer until it came of the anesthetic.

#### 2) Preparation of pseudopregnant mouse as surrogate mother

Before the test day, an ICR female mouse that had been confirmed as having  
25 estrus was cross-fertilized with the vasectomized mouse prepared in the part 1) of

Example 3. In the morning on the test day, whether a plug had been produced in the female mouse or not was observed to examine if the female mouse became pseudopregnant.

### 3) Embryo transfer into oviduct

5 The fertilized ova prepared in the part 2) of Example 2 were arranged in a line to a micropipette. The integument and muscularis of the anesthetized female mouse as a surrogate mother were slightly incised, and the ovary, the oviduct and the upper portion of the uterine horn were drawn out of the body using a pincette. The ovary was positioned in such a manner that a portion exposed through the ovarian  
10 cyst faces upward. Then, adipose tissue was inserted using a styptic device to fix the ovary. Under a stereoscopic microscope, the membrane of the ovarian cyst was removed, after which the oviduct and the ovary were drawn to look for fimbriae. Then, the front tip of the transplantation pipette was inserted 2-3 mm into the oviduct, and the fertilized ova were carefully implanted into the oviduct together with  
15 medium. Whether a first bubble, as a marker, of two bubbles in the pipette had been inserted into the oviduct was observed to examine if the fertilized ova were surely implanted into the oviduct.

Descendants were obtained from the surrogate mother mouse. To screen transgenic mice among them, Northern analysis was performed using the exons 1 and  
20 2 of EPO as probes, and the analysis results showed that 12 of 76 mice were transformed.

The expression pattern of an EPO protein for the transgenic mice was examined and the results showed that the EPO protein was expressed in a bladder-specific manner.

Example 6: Production of human EPO from inventive transgenic mouse

1) Examination of expression level of EPO in urine of inventive transgenic mouse

To examine the expression level of EPO in the urine of the inventive transgenic mouse, urine was obtained from the transgenic mouse, and filtered and then subjected to HPLC analysis. To examine the protein components of each fraction, electrophoresis and Western analysis were performed and the results are shown in FIG. 7.

As is evident from the electrophoresis results in FIG. 7a and the Western analysis results in FIG. 7b, the urine obtained from the transgenic mouse of the present invention contained a high concentration of EPO.

The concentration of EPO in the urine was calculated to be an expression level of 0.5-1 mg/ml, which is remarkably higher than the protein expression level in milk that can be seen in the existing transgenic animal.

As a result, the transgenic animal prepared using the inventive promoter can produce a target protein in its urine at excellent efficiency.

2) Examination of physiological activity of EPO obtained from inventive transgenic mouse

To examine the physiological activity of EPO obtained from the transgenic mouse of the present invention, EPO obtained in the part 1) of Example 3 was added to EPO-dependent hepatocyte cells and cultured. At this time, a control group was added with commercially available EPO. At each of 24, 48 and 72 hours after the culturing, the survival rate of the cells was measured and the results are given in Table 1 below.

Table 1:

Culturing time	DMEM/F12 (%)	FBS	FBS + commercial EPO	FBS + inventive EPO
24	38.5 ± 6.8	54.9 ± 4.3	58.2 ± 6.6	72.1 ± 4.7
48	21.6 ± 7.4	39.9 ± 2.9	50.0 ± 2.4	60.4 ± 7.5
72	10.0 ± 4.6	20.8 ± 11.7	39.6 ± 3.8	53.9 ± 4.0

As shown in Table 1, it was observed that EPO isolated from the urine of the inventive transgenic mouse showed a higher physiological activity than the commercial EPO in all the time zones.

5 As a result, the use of the transgenic animal prepared using the promoter of the present invention allows the production of a protein having a far superior physiological activity to a protein that can be obtained by the existing method.

10 Example 6: Production of inventive expression vector containing regulators, and examination of its efficiency

1) Construction of expression vector containing regulators

In order to establish a vector system that can maximize EPO production under the regulation of the inventive UPII promoter, a selective marker and regulators were introduced into the pUP2/hEPO vector in the following manner to  
15 produce a series of improved vectors.

1-1) Construction of pUPII/hEPO-Neo vector

In order to insert an efficient selective marker into a vector in the establishment of a cell line that can express a protein under the regulation of the UPII promoter, a neomycin-resistant gene was introduced in the following manner so as to  
20 produce a pUP2/hEPO-Neo vector.

To obtain the neomycin-resistant gene, PCR reaction was performed using a

pEGFP-N1 vector (Clontech) as a template, and a forward primer (SEQ ID NO: 8) and a reverse primer (SEQ ID NO: 9).

5' - GCGGCCGCGCGCTCAGGTGGCAC - 3' (SEQ ID NO: 8)

5' - CGATCGGACGCTCAGTGGAAACGAAACTC - 3' (SEQ ID NO: 9)

5 The resulting 1.9-kb PCR product was inserted into a pGEM T-easy vector and digested with a NotI restriction enzyme, to prepare the neomycin-resistant gene portion to be used in cloning.

The ampicillin-resistance gene site of the inventive pUP2/hEPO vector was removed by digestion with NotI and SalI restriction enzymes, to prepare a vector to  
10 be used in cloning.

The neomycin-resistant gene prepared as above described was cloned into to the vector, thereby producing the pUP2/hEPO-Neo vector where the neomycin-resistant gene was inserted into the existing pUP2/hEPO vector.

#### 1-2) Construction of I/pUP2/hEPO vector

15 In order to obtain an expression vector which can stably express a protein under the regulation of the UP2 promoter, an insulator gene was introduced into a pUP2/hEPO-Neo vector in the following manner so as to produce an I/pUP2/hEPO vector.

To obtain the insulator gene, PCR reaction was performed using a pBC1  
20 vector (Invitrogen) containing a chicken B-globin insulator gene, as a template, and a forward primer (SEQ ID NO: 10) and a reverse primer (SEQ ID NO: 11). To increase PCR efficiency, two copies were amplified.

5' - TCGACTCTAGAGGGACAG - 3' (SEQ ID NO: 10)

5' - CTCCTGACTCCGTTCT - 3' (SEQ ID NO: 11)

25 The resulting 2.4-kb PCR product was inserted into a pGEM T-easy vector



and digested with a NotI restriction enzyme, to prepare the insulator gene to be used in cloning.

The insulator gene prepared as described above and the vector of the above part 1-1) were coupled to each other by a NotI site, thereby producing the  
5 I/pUP2/hEPO vector (FIG 8).

#### 1-3) Construction of pUP2/hEPO (WPRE) vector

In order to obtain an expression vector that can express a protein at large amounts under the regulation of the UPII promoter, a WPRE gene was introduced into the pUP2/hEPO-Neo vector in the following so as to produce a pUP2/hEPO  
10 (WPRE) vector.

To clone the WPRE gene, PCR reaction was performed using a forward primer (SEQ ID NO: 12) and a reverse primer (SEQ ID NO: 13).

5' - ACCAGGTTCTGTTCCTGTTAATCAACCTC - 3' (SEQ ID NO: 12)

5' - CTCGAGGAGCCCGAGGCGAAACAGGCG - 3' (SEQ ID NO: 13)

15 The resulting 0.6-kb PCR product was inserted into the pGEM T-easy vector and then inserted into the NcoI restriction site of the pUP2/hEPO-Neo produced in the part 1-1) of this Example. The resulting vector was digested with a BspHI restriction enzyme, to prepare the WPRE gene to be used in cloning.

Meanwhile, the backside of the EPO gene of the inventive pUP2/hEPO  
20 vector was digested with an NcoI restriction enzyme, to prepare the vector to be used in cloning.

The WPRE gene prepared as described above was cloned into the vector, to produce the pUP2/hEPO (WPRE) vector (FIG. 9).

#### 1-4) Construction of I/pUP2/hEPO (WPRE) vector

25 In order to produce an expression vector that can satisfy all the maximization

of expression level, the stabilization of expression and the establishment of an efficient cell line under the regulation of the UPII promoter, an I/pUP2/hEPO (WPRE) vector was produced in the following manner.

The insulator gene prepared in the part 1-2) of this Example was coupled with the vector of the part 1-3) of this example by a NotI site, thereby producing the I/pUP2/hEPO vector (FIG 10).

## 2) Examination of efficiency of inventive expression vectors

The efficiency of the expression vectors produced in Example 6 was examined in the following manner.

### 2-1) PCR analysis for inventive expression vectors

To examine the expression level of the EPO gene, which is caused by inventive expression vectors, real-time PCR was performed as follows.

The four inventive expression vectors produced in Example 6 were introduced into bladder cell line RT4 using a transfection Kit (Effectene, Qiagen) and then subcultured to establish stable cell lines. Genomic DNA was extracted from each of the resulting cell lines and subjected to PCR to examine if the transfection was properly made.

To examine the expression level of the EPO gene, total RNA was extracted from the four cell lines and subjected to RT-PCR to amplify cDNA. The PCR was performed using the above cDNA as a template, and forward and reverse primers capable of amplifying the exon region of EPO.

To examine the expression level in each of the cell lines, this process was repeated three times using, as a control group, GAPDH that is a house keeping gene which is expressed in cells at a constant level. The test results were statistically processed using a SAS program and shown in FIG 11 (pUP2 = pUP2/hEPO vector;

IUP2 = I/pUP2/hEPO vector; PW = pUP2/hEPO (WPRE) vector; and IW = I/pUP2/hEPO (WPRE) vector).

As shown in FIG 11, the inventive expression vectors showed EPO gene expression level that is higher in the order of the pUP2/hEPO vector, the I/pUP2/hEPO vector, the pUP2/hEPO (WPRE) vector, and the I/pUP2/hEPO (WPRE) vector.

Particularly, the I/pUP2/hEPO (WPRE) vector which contains both the WPRE and the insulator showed about 50 times higher expression level than the pUP2/hEPO containing no separate regulators (FIG 11b).

As a result, the inventive expression vectors, including the I/pUP2/hEPO (WPRE) vector, can be advantageously used for the production of EPO.

#### 2-2) Western analysis for inventive expression vectors

To examine the expression level of EPO protein caused by the expression vectors of the present invention, Western analysis was performed as follows.

The cell lines which had been established by introducing the respective expression vectors of the present invention in the part 2-1 of Example 6 were placed in a lysis buffer containing NP-40 and sonicated to extract proteins from the cell lines.

Each 40  $\mu$ l of the proteins were electrophoresed on SDS-PAGE gels, transferred to a PVDF membrane, and then treated with an EPO antibody to examine the expression level of an EPO protein. To quantify the expression level of the EPO protein, this process was repeated two times using an antibody for actin as a control group. The results were statistically processed with a SAS program and shown in FIG 12 (pUP2 = pUP2/hEPO vector; IUP2 = I/pUP2/hEPO vector; PW = pUP2/hEPO (WPRE) vector, and IW = I/pUP2/hEPO (WPRE) vector).

As shown in FIG. 12, the expression vectors of the present invention showed the expression level of EPO protein, which is higher in the order of the pUP2/hEPO vector, the I/pUP2/hEPO vector, the pUP2/hEPO (WPRE) vector, and the I/pUP2/hEPO (WPRE) vector.

5 This result coincides with the results shown in the part 1) of Example 7.

As a result, the inventive expression vectors, including the I/pUP2/hEPO (WPRE) vector, can be advantageously used for the production of EPO.

#### Industrial Applicability

10 As described above, the promoter of the present invention induces the bladder-specific expression of a target protein, and expresses the target protein in urine at a far higher concentration than the existing method.

The animal, which was transformed with the expression vector consisting of the inventive promoter and the target protein being regulated by the promoter,  
15 secretes the target protein in urine at a far higher efficiency than that of the existing transgenic animal. Furthermore, the protein obtained from the transgenic animal of the present invention shows a superior physiological activity to the same kind of the existing protein.

As a result, the promoter of the present invention, and the expression vector  
20 and transgenic animal using this promoter, can be advantageously employed in the production field of useful proteins that are medically valuable.

ET/KR2003/002339

RO/KR 05.01.2004

1/1

PCT

03PP181

Original (for SUBMISSION) - printed on 04.11.2003 02:37:30 PM

0-1	Form - PCT/RO/134 (EASY) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis)	
0-1-1	Prepared using	PCT-EASY Version 2.92 (updated 01.04.2003)
0-2	International Application No.	
0-3	Applicant's or agent's file reference	03PP181

1	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
1-1	page	8
1-2	line	16
1-3	Identification of Deposit	
1-3-1	Name of depositary institution	Korean Collection for Type Cultures
1-3-2	Address of depositary institution	52, Oun-dong, Yusong-Ku, Taejon 305-333, Republic of Korea
1-3-3	Date of deposit	17 October 2002 (17.10.2002)
1-3-4	Accession Number	KCTC 10352BP
1-4	Additional Indications	NONE
1-5	Designated States for Which Indications are Made	all designated States
1-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

## FOR RECEIVING OFFICE USE ONLY

0-4	This form was received with the International application: (yes or no)	
0-4-1	Authorized officer	

## FOR INTERNATIONAL BUREAU USE ONLY

0-5	This form was received by the International Bureau on:	
0-5-1	Authorized officer	

**What Is Claimed Is:**

1. A porcine uroplakin II gene promoter having a base sequence of SEQ ID

NO: 1:

5 [SEQ ID NO: 1]

gggctaggagtggaatcagagctggcctatgccacagcaacgcagaatccaaaccacatctccgacctaca  
ccagaccgtcaccataacacaggatccttaaccactgagcaaggctcaggatcaaaccctcctcatggatactagt  
cgggttcttaaccgctgagccacagtgggcactcctgttttgtgtcttctgttttggctgcatctgcagcatacagaa  
gttctgggttaaggattgaacctatgccacagcagcaaccggccacagcagtgacaacagcctgaccttaactgct  
10 - āgācācācāgggaacgcccctcaacttttcatgccttggaaccctgagtcagtacaacctgacaatgntttttttttt  
tttttgccttttctagggccacttcccgcggcatgtggagattcgaggctanaggctaatcgagctgtagccaccggc  
ctacaccagagccatagcaacgaggatccgagccgagtcgtgcaacctacactacagctcatggcaacaccggatcgtt  
aaccactgagcaaggccagggtatcgaaccgcaacctcatggttcctagtcatgattcgttaaccactgcacatgaca  
ggaaactcccaacctgacaattttatcattctgcacctagtgtgtgagtaattgaaaaattcccaagatgcaaggctcagtgt  
15 gatggtaattttatgtgtcaacctgactaggccatgttcccggatgtggagtcattgttatcttgatgttactgtgaagatat  
gttttgatgaaattaacatttaaatcagtgggggaaaaaagaagttctcgttctggtgcatcagaaacaaatccgacta  
ggaaacaagcgggtgcaggttcgatccctggcctcacttagtgagtcaggatctggcgttgccgtgagctgtgttacag  
gtggcagatgcagctcggatctagcattgtgtggtgtggtgtaggccagcagctgtagctctgattaaacccaagtct  
gggaacctccatagccgtgggtgtggccgaaaaagcaaaaaataataataataaatttaaccaggggattttgag  
20 caaagcagattacccataatatgggtgggtctcatcaagttcattgtaggccctagtggaaacaaagaccgacctccacctt  
ctccccatgagaaggaaagaattctgcaaaaagaccgccttnggacntaaactgcaactctttcctgagttccagcatgtt  
ggcctccccatcagactttggacttgccaagcctccgcaattgcatgagccaattccttaaaataaatccgtctatatatac  
acatcctgttggttctgtttctccagagaaccctgactaacgcagctctgacccctgaagaccagtgtgtccccacactcagc  
tggtgtcacctcāaacactcagccttctcaaggctcttctagctgtgtcctcctctcccacaacagctgtttcaaacctc  
25 tccccctctcagggcgcaatcccttctcctccctgagtttctacttcccagagaaagcagagaccttcaggagtgtgct

gccttaacttactcttcatccctcagccttgcaaaagtataagctttctctgcaccactgccccattcttctctgcagacag  
ggtcatttcttaaagccaaacgctaagccctccacctctgatctgagtcacatcttttccctctccagaagcttctcataaatt  
ctaccccccttttcttcttatttattctttgaaaacaaaatggaagacagccttcccgttggtgcagcggaaacagtggtg  
ccttggaaagcgctgggacgcaggttcgacccctggcccagcatagtaggttaaggatccagtgttccacagtttggctt  
5 agattgaaactgcagctcagatctggtccttggcctgggaacttcatacggcacaggacggccaaaaaagaaaagaaag  
aaaaataaaaaacaaaacagaaaagcccttctgtaccccccaattccctccagttatctctcttcccttcccagccaag  
ctctgcaaagagcggcttgcacagttctaactctacctctcccagttggccctggactttctcagtctggcttctacccccct  
caccctgtaggaatctgcttgaaggacacgcacccctcacgatccttggcccaggacatttttgtaccagccttcaatc  
ctgaccttcataatcatccgacacctcctttgtgaaacctccatccactttctcctggttccccctctaagacccattccgcctt  
10 cttcagccccctccctccatctgtcctttagatgccgactttcctagtatcctgtcctgcgcggncctgctcttccctccacaa  
ctctcttcaaggactcttttccatgtgcgatttggccatggcccaccttccctcttttaccagacttccccgggtctcc  
agactcatagactcaattatgaaaacatagttttcatctgatttgcccaagatattgcattagtattactgtataacagcttctc  
cccaatttagtggttataaaataaacacttattctgagaatcagaaacctaggcaggacatagttggggctcatgaagtt  
gcaactgaaaatgtccccctgggctaatcatacggaggactgaccagggtggaggatctgtccaagctcattcattcaca  
15 tggccgtaggttgagacagctcttctctggaacttggcaggagcctcaattccttgcacgtggacctccccctggagggg  
gtcccatgtcctccatggtgagtaatccatgagagcaagggtggaagggtgcatgccatttaggacctagcctcaggaggg  
acctacgtcacttctgtttagtctgttggccacacagactaacctgacacaaatgcacccatccatgacctgttgcagtc  
catttccacactgtttccagaatgataattacataagtaaaactcctcaaaggcttttgagattttttccattatagttgattta  
taacctcagaggcttttgtttctcagcataaaaaccaagttccttaacatagcatgtaaccacactggccaccctgccagt  
20 gctagaactctcaccatgtccatccttgaatactgcttttagccaagagctattgtttgcagttccagaatgtgtcgggata  
actcacatctctgagcctttcatgtgctgttccctcacttgggaatatcccccttcatttaggaaggctaatgtccattcattntc  
caaaactcagaagcaaattttttttttttttttttttttggcttttagggccgaactctcagcatatggagggtcccaggtta  
gccatcaaatggaattgtagctgtggttccctacaccacagccatagcaaacaccagacccaagtcacatctgcaacctacat  
cacagatcatggcaatactggatccttaaccactgagtggccaggatcaaacacaaattctcatgatactgccag  
25 gttcattaccactgagccacaacaggaaactccttcttctttatggtcacacctgcagcatatggaagtctctgggcccagg

attgaatctgagtggcagctgtgacaatgccgtafcctttaaltcactgtgctgggctgaggggntaaantgcccctcctaa  
aaaacctgagctgctgcagttggattcttaactgcaccacaagggggaaggtaagaactgtcttgccatctctgtat  
ctatcacctagcatagtaccacatagagaagttgctcaacaatgtttactgaatgaataaatgcatgagctggagttcc  
cattgcggctcagcagtaacaaacctgactagcattcataagaactgggttcgatccctagcctcagtgaggtaaggatgc  
5 agcattgctgtgagctgtggtgtaggtgcgagacgacactcagatcccacattgtctgactgtggcgcagggccctct  
gtagctctgattcgactcctagcctgggaacgtccatgccacaggtgagggcctaaaaagaaataaataagcaagcaa  
gtaagcaagcaggcagttcttggtccctgtacccctgtggcctgtgtgtatacaagtaacagctgatccatgtctcagtc  
atgttccccctcagactaccttccctgccccatctcctttgacataattgaaaaacaaatcagaattttgtcccactacc  
ttcttgctagctctgtggccttggaagctatttaltgctctgagcctctaatttcatctgcaccaaggattaataaaaagg  
10 agaggataagatgaattactatattaataatttgaaccagatactgtgctaggcactctaaataaattagcttgagtata  
gtcatagtatcctggtgagacagatttttttctttatggttgacgtgcaacatatggaagtctgggctggggcgaat  
tggagctgcagggtgcttgcctatgccacagccatggcaacatatacaaaaccgcacctgtgacctacaccagattgc  
agcaacgctggatccttcaccaaggagcaaggccagggaatcaaatgtgcatcctcacaacactatgtccggttttaac  
ccgctgagccacaccaggaaactccatggcgagacagattttatactctgtctacagaagaggaaagtgaagctcagaatg  
15 gttaggtaggtaacttggccaagatcaaaaaattcaagaagatttggggcaagtgtgtatatcatggcagcattagaaaa  
aataaagaagcatccactgtttccaacactgaacaactgagatttcttactctcacagcttttccagcttcataccaagga  
cagacgctctgccattttcccatcagaccaatatttctgaacactgcacctttacttttaggtccaagtcaccaggggtttcc  
cagtttgctcctacagattctgacactatctccacattttttgcacctttattttaagcattttatacctgtcataccttgctaga  
taaatgggaaggaaatgaatcttccatttataggtagaaaaattgaggttcaaaagtactcacaaaagtcatatagcatca  
20 ctctcaacaggaggacagcagctcccccacagagggtaacatgtccatggagcctagtggacacattttctaactgactg  
ggaagcagcagagtggtattgtgaaggggaatcataggtatatcaaacagacttaggttctgatccgagctattctgcttg  
caacaaccatagttcaatttaaaaaaaaaaagaaagaaagaaagaaagaaaggagcccccctcctggtgcagtgga  
acaaattcaactaggaactgtgaggttggtggttcgatccctggccttgctcagtgaggtaaggatctggcgttgccatgag  
ccgtggtgtaggttgacactcaactcagatctggcgttgctgtgactgtggctgtgatgtaggtggcagctgtaactccg  
25 gttagaccccagcctgggaacctccatatgcaacctccatatgcggtgggtgtggccctaaaaagaaaaaaaaaaaaaa



[illegible]

ggccgtgcctgtggcataggaagtcccagggtagggtccaatgggagctgtagccccggcctacgccacagcca  
 cagcaatgtgggaictgagccacgtctgcaacctacaccacagctcacggcaacaccagatccttaaccactgagcaa  
 ggccagggaicgagcccacgtcctcatggatgctagttgggttcgttaaccgtgagccatgatgataactcctctttctatt  
 ctttagtcacaaacagtcaacaaagggtgctgaccaaggctgacgtgcccacccccagccccagactgggccagt  
 5 gcccacccttgggtctcttgaaatcctgcccagcatcaattggctccactctccaggagatgggaagccctgtggc  
 ccctgggactcacaccctctgcatctccagagtgcaggacctggcttcaggagacaccaagaactggctccccgg  
 ctctgtgccccacccttactaccagtttctctccattcctgcccagtcaggccccctggggttactctctctctgt  
 acaccagtgaacctcagaacctgcttccctctgggaacaccactaccacgtgggagaaggggtcgtctaggggtg  
 ggccccagatacactgtaagcaggaacacagagcccttacatgtgggtgtcccggaagaaggggtttccaccccc  
 10 cgttttagtcacctgccccctctgcagctgctgagccaccaagaccagccaaggctcctgccttctggcctgagggc  
 cagctccccatcctgaaaaacctgtctgggggcctcccctgaggctgtagggcccaaggcctcccctgaggctgtagg  
 cccaaggggcaggtgaacaggattcccctctgcccctctacccccaggacaaaaccagagccccaggacagggc  
 ctcacttgctcaggaaaccacagcttgccagacccagcccagcaccagcccagct

15 2. The uroplakin II promoter of Claim 1, which is one selected from  
 functional equivalents which have one or more disruption, deletion, insertion, point,  
 substitution, nonsense, misense, polymorphism or rearrangement mutation occurred  
 in the base sequence of SEQ ID NO: 1.

20 3. An expression vector comprising the base sequence of the promoter of  
 Claim 1 or 2 and a base sequence coding for a target protein at the 3' end of the  
 promoter.

25 4. The expression vector of Claim 3, wherein the target protein is human  
 erythropoietin (EPO).

5. The expression vector of Claim 4, which is the expression vector pUP2/hEPO deposited under the accession number KCTC 10352BP.

6. The expression vector of Claim 4, which is an I/pUP2/hEPO vector containing a neomycin-resistant gene of SEQ ID NO: 5 as a selective marker, and an insulator of SEQ ID NO: 6 at the 5' end of the UPII promoter:

[SEQ ID NO: 5]

gcggccgcgcgtcaggtggcacttttcggggaaatgtgcgcggaaccctattgttttttctaataca  
ttcaaatatgtatccgctcatgagacaataaccctgataaatgctcaataattgaaaaaggaagagtcctgaggcggaa  
10 agaaccagctgtggaatgtgtgtcagttagggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcat  
gcatctcaattagtcagcaaccaggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatctc  
aattagtcagcaaccatagtcctcccccctaactccgccatcccgcccctaactccgccagttccgccatttccgccc  
catggctgactaatttttttattatgcagaggccgaggccgctcggcctctgagctattccagaagtagtgaggaggctt  
tttggaggcctaggcttttgcaaagatcgatcaagagacaggatgaggatcgttcgcatgattgaacaagatggattgca  
15 cgcaggtttccggccgcttgggtggagaggctattcggctatgactgggcacaacagacaatcggctgctctgatgccg  
ccgtgttccggctgtcagcgcaggggcgccgggtctttttgtcaagaccgacctgtccggtgccctgaatgaactgcaag  
acgaggcagcgcggctatcgtggctggccacgacggcggttccttgcgcagctgtgctcagctgtcactgaagcgg  
gaagggactggctgctattgggcgaagtgccggggcaggatctcctgtcatctcaccttgctcctgccgagaaagtatcc  
atcatggctgatgcaatgcggcggctgcatacgttgatccggctacctgccattcgaccaccaagcgaacatcgcat  
20 cgagcgagcacgtactcggatggaagccggtctgtcgtatcaggatgatctggacgaagagcatcaggggctcgcgcc  
agccgaactgttcgccaggctcaaggcgagcatcccgacggcgaggatctcgtcgtgacctatggcgatgcctgcttg  
ccgaatatcatggtggaaaatggccgcttttctggattcatcgactgtggccggctgggtgtggcggaccgctatcaggac  
atagcgttggctacccgtgataatgctgaagagcttggcggcgaatgggctgaccgcttctcgtgtttacggtatcgccg  
ctcccgatcgcagcgcacgccttctatgccttcttgacgagttctctgagcgggactctggggtcgaaatgaccgac  
25 caagcgacgcccacctgccatcacgagatttcgattccaccgcccttctatgaaaggttgggcttcggaatcgttttcc

gggacgccggctggatgatcctccagcgcggggatctcatgctggagtcttcgccaccctagggggaggctaaactga  
aacacggaaggagacaataaccggaaggaacccgcgctatgacggcaataaaaagacagaataaaacgcacgggtgtg  
ggtcgtttgtcataaacgcggggttcgggtcccagggtggcactctgtcgataccccaccgagacccattggggccaa  
tacggccgcgtttcttctttcccccaccccccacccaagttcgggtgaagggccagggtcgcagccaacgtcggggc  
5 ggcaggccctgcatagcctcaggttactcatatatacttttagattgatttaaaacttcattttaatttaaaaggatctaggtga  
agatccttttgataatctcatgacaaaatcccttaacgtgagtttctgtccactgagcgtccgatcg

[SEQ ID NO: 6]

tcgactctagaggacagccccccccaaagccccagggtgtaattacgtctctccccgctaggggca  
gcagcgagccggccggggtccgctccgggtccggcgtccccccgcatccccgagccggcagcgtgcggggacag  
10 cccgggcacggggaagggtggcacgggatcgcttctctgaacgcttctcgtgctctttgagcctgcagacacctgggg  
ggatacggggaaaaagctttaggtgaaagagagattagaatgacagaatcatagaacggcctgggttgcaaaggagc  
acagtgtcatccagatccaacccctgctatgtgcagggtcatcaaccagcagccaggctgccagagccacatcca  
gcctggccttgaatgcctgcagggtggggcatccacagcctccttgggcaacctgttcagtgcgtcaccacccctctggg  
ggaaaaactgcctcctcatatccaacccaacctccctgtctcagtgtaaagccattccccctgtcctatcaagggggag  
15 tttgtgtgacattgttggtctggggtgacacatgtttgccaattcagtgcatcacggagaggcagatcttggggataagga  
agtgaggagacagcatggacgtgggacatgcagggtgtgagggtctgggacactctccaagtcacagcgttcagaaca  
gccttaaggataagaagataggatagaaggacaaagagcaagttaaaacccagcatggagaggagcacaaaaaggcc  
acagacactgctgtccctgtgtctgagcctgcatgtttgatggtgtctggatgcaagcagaaggggtggaagagcttgcc  
tgagagatacagctgggtcagtaggactgggacaggcagctggagaattgcatgtatgttcatacaatcgtcaaat  
20 catgaaggctggaaagcctccaagaatccccaagaccaacccaacccaccaccgtgccactggccatgtccctcagt  
gccacatccccacagttcttcatcacctccagggtgacgtgacccccccacctccgtgggcagctgtgccactgcagcac  
cgctctttggagaaggtaaatcttgctaaatccagcccgacctccctggcacaacgtgaaggccattatctctcatccaac  
tccaggacggagtcagtgaggatggggtcttagaggacagccccccccaaagccccagggtgtaattacgtccc  
tccccgctaggggcagcagcgagccgcccggggtccgctccgggtccggcgtccccccgcatccccgagccggc  
25 agcgtgcggggacagccgggcacggggaagggtggcacgggatcgcttctctgaacgcttctcgtgctctttgagc

ctgcagacacctgggggatacggggaaaaagcttaggctgaaagagagattagaatgacagaatcatagaacggc  
 ctgggttgcaaaggagcacagtgtcatccagatccaacccctgctatgtgcagggtcatcaaccagcagccaggct  
 gccagagccacatccagcctggccttgatgcctgcaggatggggcatccacagcctcctgggcaacctgttcagt  
 gcgtcaccacccctcgggggaaaaactgcctcctcatatccaacccaacccctcctgtctcagtgtaaagccattccccct  
 5 tgtcctatcaaggggagttgtgtgacattgttggtctggggtgacacatgttgccaattcagtgcatcacggagaggc  
 agatcttggggataaggaagtgcaggacagcatggacgtgggacatgcagggtgttgagggtcttgggacactctcaa  
 gtcacagcgttcagaacagccitaaggataagaataggatagaaggacaaagagcaagttaaaccagcatggag  
 aggagcacaaaaggccacagacactgtgtccctgtgtctgagcctgcatgtttgatgggtgtctggatgcaagcagaa  
 ggggtccatgtccctcagtgccacatccccacagttcttcatcacctccaggagcggtagccccccacctccgtgggca  
 10 gctgtgccactgcagcaccgctcttggagaaggtaaattctgttaaattccagcccagccctccctggcataaacgtaag  
 gccattatctctcatccaactccaggaacggagtcagtgag

7. The expression vector of Claim 4, which is a pUP2/hEPO (WPRES) vector  
 containing a neomycin-resistant gene of SEQ ID NO: 5 as a selective marker, and a  
 15 woodchuck hepatitis virus posttranscriptional regulatory element (WPRES) of SEQ ID  
 NO: 7 at the 3' end of the EPO gene:

[SEQ ID NO: 7]

accaggttctgttctgttaatcaacctctggattacaaaatttgtgaaagattgactggattcttaactatgttgct  
 cttttacgctatgtggatacgtgctttaatgcctttgtatcatgctattgcttccgtagtgctttcattttctcctctgtataa  
 20 atcctgggtgctgtctttatgaggagttgtggccgtgtcaggcaacgtggcgtggtgtgactgtgttgctgacgcaa  
 cccccactgggtggggcattgccaccacgtgcagctccttccgggactttcgtttccccctccctattgccacggcgga  
 actcatcgccgctgcctgcccgtgtgagacaggggctcggtgttgggactgacaattccgtggtgtgtcggggga  
 agctgacgtcctttcatggctgtcgcctgtgtgccacctggattctgcggggacgtccttctgtacgtcccttcggcc  
 ctcaatccagcggaaccttctcccgccgctgtgccggctctgcggccttccgcttctgccttcgccctcagacg  
 25 agtcggatctcccttgggcccctccccgcctgtttcgctcgggctcctcgag

8. The expression vector of Claim 4, which is an I/pUP2/hEPO (WPRE) vector that contains a neomycin-resistant gene of SEQ ID NO: 5 as a selective marker, an insulator of SEQ ID NO: 6 at the 5' end of the UP2 promoter, and an  
5 WPRE of SEQ ID NO: 7 at the 3'-end of the EPO gene.

9. An animal's fertilized ovum introduced with the expression vector of any one of Claims 4 to 8.

10 10. A transgenic animal obtained by the implantation of the fertilized ovum of Claim 9.


11. The transgenic animal of Claim 10, which is one selected from the group consisting of porcine, mouse, bovine, poultry, ovine and caprine animals.

15

12. A method for producing useful proteins, which comprises the steps of:  
implanting the animal's fertilized ovum introduced with the expression vector of any one of Claims 4 to 8 into a surrogate mother animal; and  
obtaining transgenic animals from the surrogate mother animal; and  
20 isolating and purifying useful proteins from the urine of the transgenic animals.


[DRAWING]

[FIG 1]




Porcine UPII promoter : 8847kb

[FIG 2]




pUP2/hEPO Expression Vector

[FIG 3]




[FIG 4]

**a**




**b**






[FIG 5]





[FIG 6]



[FIG 7]

**a**




**a: 496508.9**

**b: 0.1695**


**c: 191863.3**

**d: 0.0262**

**b**




[FIG. 8]




**pUPII/hEPO (IUP2)**

[FIG. 9]




**pUPII/hEPO/WPRE (PW)**


[FIG 10]



[FIG 11]



[FIG 12]



## Sequence Listing

---

<110> CHO-A PHARM CO., LTD.  
KIM, Jin Hoi

<120> Porcine uroplakin II promoter and the production method of useful  
proteins using said promoter

<130> 03PP181

<150> KR 10-2002-0067856  
<151> 2002-11-04

<150> KR 10-2003-0077256  
<151> 2003-11-03

<160> 13

<170> KopatentIn 1.71

<210> 1  
<211> 8847  
<212> DNA  
<213> Sus scrofa

<220>  
<221> promoter  
<222> (1)..(8847)  
<223> porcine uroplakin II promoter

<400> 1

gggctaggag tggaatcaga gctggcctat gccacagcaa cgcagaatcc aaaccacatc 60

tccgacctac accagaccgt caccataaca caggatcctt aaccactga gcaaggtcag 120

ggatcaaacc caaatcctca tggatactag tcgggttctt aaccogctga gccacagtgg 180

gcactcctgt ttttgtttgt gtcttcgttt tttggctgca tctgcagcat acagaagttc 240

ctggggttaag gattgaacct atgccacagc agcaaccga gccacagcag tgacaacagc 300

## Sequence Listing

ctgatcctta actgctagac caccagggaa cgccectca acttttcacg cettggaaac 360  
cctgagtcag tacaacctga caatngnttt tttttttttt tttttttgcc ttttctaggg 420  
ccacttcccg cggcatgtgg agattcgag gctanaggtc taatcggagc tgtagccacc 480  
ggcctacacc agagccatag caacgagga tccgagccga gtctgcaacc tacactacag 540  
ctcatggcaa caccggatcg ttaaccact gagcaaggcc aggggatcga acccgcaacc 600  
tcattggttc tagtcagatt cgttaaccac tgcacatga caggaactcc caacctgaca 660  
atattatcat ttctgcaccc tagttgttga gtaatttgaa aaattcccaa gatgtcaagg 720  
tcagtgtgat ggttaatttt atgtgtcaac ctgactaggc catgttgccc gtagtggag 780  
tcattgttat tctggatgtt actgtgaaga tatgttttgg atgaaattaa catttaaate 840  
agtgggggga aaaaaagaag ttctcgttct ggtgcatcag aaacaaatcc gactaggaaa 900  
caagcgggtg caggttcgat cctcggcctc acttagtgga gtcaggatct ggcgttgccg 960  
tgagctgtgg tacaggtggc agatgcagct cggatctagc attgctgtgg ctgtggtgta 1020  
ggccagcagc ttagctcttg attaaacccc aagtctggga acctccatat gccgtgggtg 1080  
tggcccgaaa aagcaaaaaa taaataaata aataaattta aaccagggga ttttgagcaa 1140  
agcagattac ccataatat ggggtgggtct catcaagttc attgtaggcc ctagtgaac 1200  
aaagacgac ctcaccttc tccccatgag aaggaaagaa ttctgcaaaa agaccgcctt 1260  
nggacontaaa ctgcaactct ttctgagtt tccagcatgt tggcctcccc catcagactt 1320  
tggacttgcc aagcctcgc aattgcatga gccaatcct taaaataaat cgtctatat 1380  
atacacatcc tgttggttct gtttctccag agaacctga ctaacgcagt ctgcaccct 1440  
gaagaccagt ggtccccaca ctgagctggg tgcacctcc aaacactcag ccttctcaa 1500

## Sequence Listing

---

ggctctttct agctgtgtcc tctctcccc acaacagctg ttccaaactc tcacccctct	1560
tcaggcgcca atcccttctc ctccctgagt ttctacttc ccagagaaag cagagacctt	1620
caggagtgtg ctgccttaac ttacttctt catccctcag ccttgcaaaa gtataagctt	1680
tctctgcacc actgccccat tcttctctct gcagacaggg tcattcctaa agccaaaagc	1740
taatgcctcc acctctgac tgagtcccat cttttccctc ctccagaagc ttctcataa	1800
attctacccc cttttcttcc ttatctttat ctttgaaaac aaaatggaag acagccttcc	1860
cgttgtgggtg cagcggaac agtgggtgct tggaaagcgt gggacgcagg ttcgacccct	1920
ggcccagcat agtaggttaa ggatccagt ttgccacagt ttggccttag attgaaactg	1980
cagctcagat ctggtccctg gcctgggaac ttcatacgcc acaggacggc ccaaaaagaa	2040
aagaaagaaa aaataaaaaa caaaacagaa aagcctttcc tgtaccccca attcctcca	2100
gttatctctc tctttccctt ccagccaag ctctgcaaag agcggctctgc acagttctaa	2160
ctctacctcc tcccagttgg ccctggactt tctcagctg gcttctacce cctcaccog	2220
taggaatctg ctctgaagga cagcacccc tcacgatect tggcccagg acattttttg	2280
taccagcctt tcaatcctga cttcatatc atccgacacc tcctttgtga aaccctccat	2340
ccactttctc ctggttcccc tctaagacc cattcgcct tcttcagccc cctccctcca	2400
tctgtccttt agatgcgca ttctctagta tctgtcctg cgcggnetcg tccttccctt	2460
ccacaactct ctcaaggac tcttttctcc atgtgegatt ttgcccattg cccaccttcc	2520
ctctctttac ccagacttcc ccccggtgct ccagactcat agactcaatt atgaaaacat	2580
agttttcatc tgatttgccc aagatatttg cattagttat tactgtataa cagcttatcc	2640
cccaatttag tggcttataa aataaacact tattctgaga atcagaaacc taggcaggac	2700



## Sequence Listing

---

atagttgggg tctcatgaag ttgcactgaa aatgtccccc tgggctaatac atacggagga	2760
ctgaccaggg ctggaggatc tgttccaagc tcattcattc acatggccgt aggttgaga	2820
cagctcttct ctggatcttg gcaggagcct caattccttg tcaegtggac ctccccttgg	2880
aggggggtccc atgtcctcca tggtagtaa tccatgagag caaggtggaa ggtgccatgc	2940
catttaggac ctagcctcag gagggacctc cgtcacttct gttgtagtct gttggccaca	3000
cagactaacc ctgacacaat gcacccatcc atgacctgct gccagtccat tctccacact	3060
gtttccagaa tgatatttac ataagtaaaa ctccctcaaag gcttttgaga ttttttttcc	3120
cattatagtt gatttataac ctgagaggct tttgttttct tcagcataaa aaccaagttc	3180
cttaacatag catgtaaccc actggccacc ctgccagtgg ctagaactct caccatgtcc	3240
atccttgaat actgctttct agccaagagc tattgtttgc agttcccaga atgtgtcggg	3300
ataactcaca tctctgagcc ttttcatgtg ctgttccctc actttggaat atccccctcc	3360
atttaggaag gctaattgtc attcatntc caaaactcag aagcaaattt tttttttttt	3420
tttttttttt tttttttgct ttttagggcc gaactctcag catatggagg tcccagggt	3480
agccatcaaa ttggaattgt agctgctggc ctacaccaca gccatagcaa caccagaccc	3540
aagtcacatc tgcaacctac atcacagatc atggcaatac tggatcctta accactgag	3600
tgagcccagg gatcaaacac aaattctcat ggatactcgc caggttcatt accactgagc	3660
cacaacagga actcctctcc tttttatggt cacacctgca gcatatggaa gttcctgggc	3720
cagggattga atctgagtgg cagctgtgac aatgccgtat cctttaattc actgtgctgg	3780
gctgaggggn taaantgcc ctcttaaaaa acctgagctg ctgcagttgg attcttaac	3840
cactgcacca caagggggaa ggtcaagaac tgtcttgcca tctctgtatc ttatcaccta	3900

## Sequence Listing

---

gcatagtacc caccatagag aagttgctca acaaatgttt actgaatgaa taaatgcatg	3960
agctggagtt cccattgcgg ctcagcagta acaaacctga ctagcattca taagaacttg	4020
ggttcgatcc ctgacctcag tgggttaagg atgcagcatt gctgtgagct gtgggttagg	4080
tgcgagacga cactcagatc ccacattgct gtcactgtgg cgcaggccgg cctctgtagc	4140
tctgattcga ctccctagcct gggaaagtcc atatgccaca ggtgaggccc taaaaagaaa	4200
taaataagca agcaagtaag caagcaggca gtttcttggt gccttgtagc cctgtggcct	4260
gtgtggtata caagtaacag ctgatccatg tctcagtcac gtttccccct cagactacct	4320
ttcttgcccc atctctccct ttgacataat tggaaaaaca aattcagaat tttgtcccac	4380
tacctttctt gctagctctg tggccttggg aaagctattt attgcctctg agcctcta	4440
tttcatctgc accaaggatt aataaaaagg agaggataag atgaattact tatattaata	4500
tttattgaac cagatactgt gctaggcact cttaaataaa ttagcttgag tgatagtcac	4560
agtatcctgg tgagacagat ttttttttct cttttatggt tgcacgtgca acatatggaa	4620
gttctctggc tggggctgaa ttggagctgc aggtgcttgc ctatgccaca gccatggcaa	4680
catcatatac aaaccgcacc tgtgacctac accacagatt gcagcaacgc tggatccttc	4740
acccaaggag caaggccagg aatcaaatgt gcatcctcac aaacactatg tccggttttt	4800
aaccgcctga gccacaccag gaactccatg gcgagacaga ttttatactc tgtctacaga	4860
agaggaaagt gaagctcaga atggttaggt aggttaacttg gccaaagatc aaaaattcaa	4920
agaagatttg gggcaagtgg tgatatcatg gcagcattag aaaaaataaa gaagcatcca	4980
cttgttttcc aacctgaac aactgagatt ttcttactct cacagctttt tccagcttca	5040
tatccaagga cagaagctct gccattttcc catcagacca atatttgctg aacactgcac	5100

## Sequence Listing

---

ctttactttt aggtccaagt caccaggggt ttccccagtt tgetcctaca gattctgaca	5160
ctatctccac attttttttg cacctttatt ttaaagcatt ttataacctg tcataccttg	5220
ctagataaat gggaaggaat gaatcttccc atttataggt gagaaaattg aggttcaaag	5280
tgactcacca aaagtcatat agcatcactc ctcaacagga ggacagcagt ccccaccaga	5340
gggtaacatg tccatggagc ctagtggaca catttttcta actgactggg aagcagcaga	5400
gtggtattgt gaagggggaa tcataggtat atcaaacaga cttaggttct gatccgagct	5460
attctgcttg caaacaccca tagttcaatt taaaaaaaa aaagaaagaa agaaagaaag	5520
aaaggagccc ccctcctggg gcagtggaaa caaattcaac taggaactgt gaggttggtg	5580
gttcgatccc tggccttgct cagtgggtta aggatctggc gttgccatga gccgtggtgt	5640
agggtgcaga ctcaactcag atctggcggt gctgtgactg tggtgtgat gtaggctggc	5700
agctgtaact ccggttagac ccagcctgg gaacctecat atgcaacctc catatgcggt	5760
gggtgtggcc ctaaaagaa aaaaaaaaa aaaagaggaa ttcccttatg gctcagcagg	5820
ttaaggatct ggtattgtca ctgctgtggc tctagttaca gccatagtgc aggttcaatc	5880
cctggcccag gaacgtctgc atcccacagg tgtggccaaa aaagaaagaa aggaaggagt	5940
tctgttgtgg cacaatagga ttggcaacat cttaggagta ctgggacaca ggttcaatcc	6000
ctggcccagc acagtgggta aggagccagt gttgctggtc aaaaaagaaa agaaaaagta	6060
ccatagttag agtaaatctg ttttaggagc tattcttttg ggcagaacag agagatcagg	6120
agctccttga gaggagaaac ttacctttac atccctcgtg cctagcacgg ttctaggggc	6180
atacctggta tttataaat atagccaact ggatagggga ttggaaggaa agagcagggg	6240
agggaaactg agtgagttga aaaattgaga atccaaaggg gagacagcct agaaagagta	6300

## Sequence Listing

ggccaagaa agagatccca ggcatttggt gccctgggtc cctttttcca agccatgagg	6360
aaatcctcag aggaacagag tgctgtggct ttaaatgact tcagcgttgt caatgaatct	6420
gctcggctaa aagagttatc ctcttgctcc ttogcttgtc ctccccctcc tctcagctcc	6480
ccaaaccctt ctoggtgct gtgatgggat aattagatgc gagagctcag cacagatgat	6540
gctccagttg cctagecaact aatggtttcc atggagaccg caaagcacag cctccagagc	6600
agccagttag cagctcggca gggcagggag aagacgcaac tctcagctcc tccagaaacc	6660
tggggagggc caggagtggg gaagaagggg gggatcggag ggttaaagg cacaggcccc	6720
tettatcttc ttaaaatctg gtcagagctc tgccctcccc tcccctactc tgtcccactc	6780
ataatttcag atggagttag gggcttagga gtggacccaa cacaacctac cctgcaataa	6840
acccaacctt ctttctgctt ctggtttgtg gctgaaaatg gnaaaagaaa tctcccaagt	6900
gcàagtgtaa acanctcct gggttggcaa tgggatctga agagtactaa gatccctcag	6960
acctggaatt ccaàcattha gtctttccct ctctccaaag ttctcaatgt gcaaaagatc	7020
ctctttcagt ttgcagagca atgataggat ctctctaaaag gagacaaaag ccaaggtgca	7080
ggaaaaatag aattcagttc ttcacccaaa ggcagcctgt cctgggagac aggggtgaaa	7140
cacttggtcc tgatctccat cagaggatcc agagtgtgtg tgtttggtgc tggggagggg	7200
gacacaatat agagcatctg gtgactcaaa gtatgtgcct cccagagtag catcaatcaa	7260
tgttacctgg aagcttgta gaaatgcaga atttcaggct tcacctcaga cccactgaat	7320
cagaaactgc atcttaacaa gatccctcat gattcatacg cacattaaat ttggagaagc	7380
gctgacctga gaccctctc ctctctgctt gggcccatag ttctacctt attgtcacct	7440
cgtctcacct cgtgctcata cccaggtt tgagcctacc cttccccca tggggaagg	7500

## Sequence Listing

---

acacaaggcc accagccct cacttccta ccaggacct ggcctcctc tgggactgga	7560
gaaggacaaa gaggacccc tctgtggagg tctacgacct ctctgacca agtagtcac	7620
tcaccacaag tggctctacc tctctgagtc tcagtttcca catccacaaa aggtggccaa	7680
tgctatctgc caccagaat ggctgtgagg gtggagcagg caaagcctct gtgccatcag	7740
agaaattgtg tctctttttc atttctccc agtgggtttc tttctgtct ttattctttt	7800
ttttttttt tttctgtc tgttgtattt ttagggcgt gcctgtggca tacggaagt	7860
cccagggtag gggccaatg ggagctgtg cccgggct acgccacagc cacagcaatg	7920
tgggatctga gccaggtctg caacctacac cacagctcac ggcaacacca gatcctaac	7980
ccactgagca aggccaggga tcgagccac gtcctcatgg atgctagtgt ggttcgttaa	8040
ccgtgagcc atgatgataa ctctctttc tattctttag tcacaaacag tcaacaaagg	8100
ttgtgacca aggtgatcg tgcccacccc ccagccccc agactgggccc agtgcccacc	8160
ccttgggtct ctctggaaat cctgcccagc atcaattggc tcactctcc aggaggatgg	8220
gaagccctgt ggcctctggg actcaccacc ctctgcactt ccagagtgc aggacctgt	8280
cttcaggaga caccaagaac tggctcccc ggctctgtg ccccccacc ctactaccag	8340
tttctctccc attctgccc agtcaggccc ccctgggggt actctctct ctctgtacac	8400
cagtgaacc tcagaacctg ctccctctt gggaaacccc actaccagt gggagaagg	8460
gtcgtctagg ggttgggccc cagatacact tgtaagcagg aacacacgag cccttacatg	8520
tgggtgtccc ggaagaagg ggttttcac ccccgcttt agtcacctg cccctctgca	8580
gctgcctgag ccaccaagac ccagccaagg tctcctgct tctggcctga gggccagctc	8640
cccatcctga aaaacctgtc tgggggctc ccctgaggct gtagggccca aggcctcccc	8700

## Sequence Listing

---

tgaggctgta gggcccaagg ggcaggttga acaggattcc cctctgccc ctcctacccc 8760

caggacaaaa ccagagcccc aggacagggc ctcacttgcc tcaggaaacc acagcttgcc 8820

agcaccacag ccagcaccag cccagct 8847

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> forward primer for amplifying porcin uroplakin II gene

<400> 2

gatcctgatt ctgctggctb 20

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> reverse primer for amplifying porcin uroplakin II gene

<400> 3

atggtggta tcacrgtgct 20

<210> 4

<211> 3602

<212> DNA

<213> Homo sapiens

<300>

<301> Lin, F. K.

## Sequence Listing

---

Suggs, S.  
 Lin, C. H.  
 Browne, J. K.  
 Smalling, R.  
 Egrie, J. C.  
 Chen, K. K.  
 Fox, G. M.  
 Martin, P.  
 Stabinsky, Z.

<302> Cloning and expression of the human erythropoietin gene

<303> Proc. Natl. Acad. Sci. U.S.A.

<304> 82

<305> 22

<306> 7580-7584

<313> 1-3602

<400> 4

aagcttcttg gettccagac ccagctactt tgcggaactc agcaaccag gcatctctga	60
gtctccgccc aagaccgga tgccccccag gggagggtgc cgggagccca gcttttccca	120
gatagcacgc tccgccagtc ccaagggtgc gcaaccggct gcactccct cccgcgaccc	180
agggcccgag agcagcccc atgaccaca cgcacgtctg cagcagcccc gtcacgccc	240
cggcgagcct caaccaggc gtcttgcctc tgccttgacc cgggtggcc cctaccctg	300
gcgacccctc acgcacacag cctctcccc accccaccc gcgcacgcac acatgcagat	360
aacagccccg acccccgcc agagccgag agtccctggg ccaccceggc cgctcgctgc	420
gctgcgcgc acgcgctgt cctcccgag cggaccggg gccaccgcgc ccgctctgct	480
ccgacacgc gccccctgga cagccgcct ctctctagg ccgtggggc tggccctgca	540
ccgccgagct tccgggatg agggccccc gtgtgggtcac ccggcgccc ccaggtcgt	600
gagggacccc ggccaggcgc ggagatgggg gtgcacggtg agtactcgc ggctgggcgc	660

## Sequence Listing

tcccgcgcgc cgggtccctg tttagagcgg gatttagcgc cccggctatt ggccaggagg	720
tggctgggtt caaggaccgg cgacttgcca aggacccgg aagggggagg ggggtggggc	780
agcctccacg tgccagcggg gacttggggg agtccttggg gatggcaaaa acctgacctg	840
tgaaggggac acagtttggg ggttgagggg aagaaggttt ggggggttctg ctgtgccagt	900
ggagaggaag ctgataagct gataacctgg gcgctggagc caccacttat ctgccagagg	960
ggaagcctct gtcacaccag gattgaagtt tggccggaga agtggatgct ggtagctggg	1020
ggtgggggtg gcacacggca gcaggattga atgaaggcca gggaggcagc acctgagtg	1080
ttgcatggtt ggggacagga aggacgagct ggggcagaga cgtggggatg aaggaaagctg	1140
tccttcacaa gccacccttc tccctcccg cctgactctc agcctggcta tctgttctag	1200
aatgtcctgc ctggctgtgg ctctcctgt cctgctgtc gctccctctg ggcctccag	1260
tcctgggcgc cccaccacgc ctcatctgtg acagccgagt cctggagagg tacctcttgg	1320
aggccaagga ggccgagaat atcacggtga gaccccttc ccagcacatt ccacagaact	1380
cacgctcagg gcttcaggga actcctccca gatccaggaa cctggcactt ggtttgggt	1440
ggagttggga agctagacac tgcccccta cataagaata agtctggtgg ccccaaacca	1500
tacctgaaaa ctaggcaagg agcaaaacca gcagatccta cggcctgtgg gccagggcca	1560
gagccttcag ggacccttga cteccgggc tgtgtgcatt tcagacgggc tgtgctgaac	1620
actgcagctt gaatgagaat atcactgtcc cagacaccaa agttaatttc tatgcctgga	1680
agaggatgga ggtgagttcc ttttttttt tttttcctt cttttggaga atctcatttg	1740
cgagcctgat tttgatgaa agggagaatg atcgggggaa aggtaaaatg gagcagcaga	1800
gatgaggtg cctgggcgca gaggctcacg tctataatcc caggctgaga tggccgagat	1860



## Sequence Listing

---

gggagaattg cttgagccct ggagtttcag accaacctag gcagcatagt gagatccccc	1920
atctctacaa acatttaaaa aaattagtca ggtgaagtgg tgcattggtgg tagtcccaga	1980
tatttggaag gctgaggcgg gaggatcget tgagcccagg aatttgaggc tgcagtgagc	2040
tgtgatcaca ccaactgact ccagcctcag tgacagagtg aggcctgtc tcaaaaaaga	2100
aaagaaaaa gaaaaataat gagggtgtga tggaatacat tcattattca ttcactcact	2160
cactcactca ttcattcatt cattcattca acaagtctta ttgcatacct tctgtttgct	2220
cagcttggtg cttggggctg ctgaggggca ggaggagag ggtgacatgg gtcagctgac	2280
tcccagagtc cactccctgt aggtcgggca gcaggccgta gaagtctggc agggcctggc	2340
cctgctgtcg gaagctgtcc tgcggggcca ggccctgttg gtcaactctt cccagcogtg	2400
ggagcccctg cagctgcatg tggataaagc cgtcagtggc cttcgcagcc tcaccactct	2460
gcttcgggct ctgggagccc aggtgagtag gagcggacac ttctgcttgc cctttctgta	2520
agaaggggag aagggtcttg ctaaggagta caggaactgt ccgtattcct tccctttctg	2580
tggcactgca ggcacctcct gttttctcct tggcagaagg aagccatctc ccctccagat	2640
gcggcctcag ctgctccact ccgaacaatc actgctgaca ctttccgcaa actcttccga	2700
gtctactcca atttctccg gggaaagctg aagctgtaca caggggaggc ctgcaggaca	2760
ggggacagat gaccaggtgt gtccacctgg gcataccac cactccctc accaacattg	2820
cttgtgccac accctcccc gccactcctg aacccegtcg aggggetctc agctcagcgc	2880
cagcctgtcc catggacact ccagtgccag caatgacatc tcaggggcca gaggaactgt	2940
ccagagagca actctgagat ctaaggatgt cacagggcca acttgagggc ccagagcagg	3000
aagcattcag agagcagctt taaactcagg gacagagcca tgctgggaag acgcctgagc	3060

## Sequence Listing

---

```

tcactcggca ccctgcaaaa ttgatgccg ggacacgctt tggaggcgat ttacctgttt      3120
tcgcacctac catcagggaac aggatgacct ggagaactta ggtggcaagc tgtgacttct      3180
ccaggctctca cgggcatggg cactcccttg gtggcaagag cccctctgac accgggggtgg      3240
tgggaaccat gaagacagga tgggggctgg cctctggctc tcatggggtc caagttttgt      3300
gtattcttca acctcattga caagaactga aaccaccaat atgactcttg gcttttctgt      3360
tttctgggaa cctccaaatc ccttggtctt gtccactcc tggcagcagt gcagcaggtc      3420
caggctcggg aaatgagggg tggagggggc tgggccctac gtgctgtctc acacagcctg      3480
tctgacctct cgacctacg gcctaggcca caagctctgc ctacgctggt caataagggtg      3540
tctccattca aggcctcacc gcagtaaggc agctgccaac cctgcccagg gcaaggctgc      3600
ag                                                                           3602

```

```

<210>      5
<211>     1916
<212>      DNA
<213>     Gallus gallus

```

```

<220>
<221>     misc_signal
<222>     (1)..(1916)
<223>     beta-globin insulator

```

```

<400>      5
gcggccgcgc gcgtcagggt gcacttttgc gggaaatgtg cgcggaaccc ctatttgttt      60
atttttctaa atacattcaa atatgtatcc gtcctatgaga caataaccct gataaatgct      120
tcaataatat tgaaaaagga agagtcctga ggcggaaaga accagctgtg gaatgtgtgt      180
cagttagggt gtggaaagtc ccagggtcc ccagcaggca gaagtatgca aagcatgcat      240

```

## Sequence Listing

---

ctcaattagt cagcaaccag gtgtggaag tccccaggct cccagcagg cagaagtatg	300
caaagcatgc atctcaatta gtcagcaacc atagtccgc ccctaactcc gcccatcccg	360
cccctaactc cccccagttc cccccattct cgcgcccatg gctgactaat tttttttatt	420
tatgcagagg ccgaggccgc ctggcctct gagctattcc agaagtagtg aggaggcttt	480
tttggaggcc taggcttttg caaagatcga tcaagagaca ggatgaggat cgtttcgcat	540
gattgaacaa gatggattgc acgcaggttc tccggccgct tgggtggaga ggctattcgg	600
ctatgactgg gcacaacaga caatcggctg ctctgatgcc gccgtgttcc ggcgtgcage	660
gcagggcgcc cgggttcttt ttgtcaagac cgacctgtcc ggtgccctga atgaactgca	720
agacgaggca gcgcggctat cgtggctggc caccaggggc gttecttgcg cagctgtgct	780
cgacgttgtc actgaagcgg gaagggactg gctgctattg ggcgaagtgc cggggcagga	840
tetctgtca tetcaacttg ctctgcga gaaagtatcc atcatggctg atgcaatgcg	900
gggctgcat acgcttgatc cggctacctg cccattcgac caccaagcga aacatcgcat	960
cgagcgagca cgtactcgga tggagccgg tctgtcgat caggatgatc tggacgaaga	1020
gcatcagggg ctgcgccag cgaactgtt cgcaggctc aaggcgagca tgcccagcg	1080
cgaggatctc gtctgaccc atggcgatgc ctgcttgccg aatatcatgg tggaaaatgg	1140
ccgcttttct ggattcatcg actgtggccg gctgggtgtg gcggaccgct atcaggacat	1200
agcgttggt acccgtgata ttgctgaaga gcttgccggc gaatgggctg accgcttct	1260
cgtgctttac ggtatcgccg ctcccgatc gcagegcac gccttctatc gccttcttga	1320
cgagtcttc tgagcgggac tctggggttc gaaatgaccg accaagcgac gcccaacctg	1380
ccatcacgag atttcgattc caccgccgc ttctatgaaa ggttgggctt cggaatcgct	1440

## Sequence Listing

---

```

ttccgggaag cgggctggat gatcctccag cgcggggatc tcatgctgga gttcttcgcc      1500
caccctaggg ggaggctaac tgaaacacgg aaggagacaa taccggaagg aaccgcgct      1560
atgacggcaa taaaagaca gaataaaacy cacggtgttg ggtcgtttgt tcataaacgc      1620
ggggttcggt cccagggtcg gcactctgtc gatacccccac cgagacccca ttggggccaa      1680
tacgcccgcg tttcttcctt tttcccaccc ccccccccaa gttegggtga aggccagggt      1740
ctcgcagcca acgtcggggc ggcaggccct gccatagcct caggttactc atatatactt      1800
tagattgatt taaaacttca tttttaattt aaaaggatct aggtgaagat cctttttgat      1860
aatctcatga ccaaaatccc ttaacgtgag ttttcgttcc actgagcgtc cgatcg      1916

```

```

<210>      6
<211>    2254
<212>    DNA
<213>    Artificial Sequence

```

```

<220>
<223>    Cloning vector pEGFP-N1, complete sequence, enhanced green
          fluorescent protein (egfp) and neomycin phosphotransferase genes

```

```

<400>      6
tcgactctag agggacagcc ccccccaaa gcccccaggg atgtaattac gtccctcccc      60
cgctaggggc agcagcgagc cggccggggc tccgctcggg tccggcgctc ccccgcac      120
cccgagccgg cagcgtgcgg ggacagcccg ggcacgggga aggtggcacg ggatcgcttt      180
cctctgaacg cttctcgtg ctctttgagc ctgcagacac ctggggggat acggggaaaa      240
agcttttagc tgaaagagag atttagaatg acagaatcat agaacggcct gggttgcaaa      300
ggagcacagt gtcacatccag atccaacccc ctgctatgtg cagggtcatc aaccagcagc      360

```

## Sequence Listing

---

ccaggctgcc cagagccaca tccagcctgg ccttgaatgc ctgcagggat ggggcatcca	420
cagcctcctt gggcaacctg ttcagtgcgt caccaccctc tgggggaaaa actgcctcct	480
catatccaac ccaaacctcc cctgtctcag tgtaaagcca ttcccccttg tccatcaag	540
ggggagtttg ctgtgacatt gttggtctgg ggtgacacat gtttgccaat tcagtgcac	600
acggagaggg agatcttggg gataaggaag tgcaggacag catggacgtg ggacatgcag	660
gtgttgaggg ctctgggaca ctctccaagt cacagcgttc agaacagcct taaggataag	720
aagataggat agaaggacaa agagcaagtt aaaaccacgc atggagagga gcacaaaaag	780
gccacagaca ctgctggtcc ctgtgtctga gcctgcatgt ttgatgggtg ctggatgcaa	840
gcagaagggg tggaagagct tgcctggaga gatacagctg ggtcagtagg actgggacag	900
gcagctggag aattgccatg tagatgttca tacaatcgtc aaatcatgaa ggctggaaag	960
cctccaagat cccaagacc aacccaacc caccacagt gccactggc catgtccctc	1020
agtgccacat cccacagtt ctctatcacc tccagggacg gtgacccccc caccctcgtg	1080
ggcagctgtg ccactgcagc accgctcttt ggagaaggta aatcttgeta aatccagccc	1140
gaccctcccc tggcacaacg taaggccatt atctctcacc caactccagg acggagtcag	1200
tgaggatggg gctctagagg gacagccccc ccccaaagcc cccagggatg taattacgtc	1260
cctccccgc taggggcagc agcgagccgc ccggggctcc gctccggtec ggcgctcccc	1320
ccgcatcccc gagccggcag cgtgcgggga cagcccgggc acggggaagg tggcacggga	1380
tcgttttct ctgaacgctt ctgctgctc tttgagcctg cagacacctg gggggatacg	1440
gggaaaaagc tttaggtga aagagagatt tagaatgaca gaatcataga acggcctggg	1500
ttgcaaagga gcacagtgc catccagatc caaccctctg ctatgtgcag ggtcatcaac	1560

## Sequence Listing

---

```

cagcagccca ggctgcccag agccacatcc agcctggcct tgaatgcctg cagggatggg      1620
gcateccacag cctccttggg caacctgttc agtgcgtcac caccctctgg gggaaaaact      1680
gcctcctcat atccaacca aacctcccct gtctcagtgt aaagccattc ccccttgtcc      1740
tatcaagggg gagtttgctg tgacattgtt ggtctggggg gacacatgtt tgccaattca      1800
gtgcatcacg gagaggcaga tcttggggat aaggaagtgc aggacagcat ggacgtggga      1860
catgcagggtg ttgagggctc tgggacacte tccaagtcac agcgttcaga acagccttaa      1920
ggataagaag ataggataga aggacaaaga gcaagttaa acccagcatg gagaggagca      1980
caaaaaggcc acagacactg ctgggccctg tgtctgagcc tgcattgttg atggtgtctg      2040
gatgcaagca gaaggggtcc atgtccctca gtgccacatc cccacagtgc ttcattacct      2100
ccaggggacgg tgaccccccc acctccgtgg gcagctgtgc cactgcagca ccgctctttg      2160
gagaaggtaa atcttgctaa atccagcccc acctcccctt ggcacaacgt aaggccatta      2220
tctctcatcc aactccagga acggagtcag tgag                                     2254

```

```

<210>      7
<211>      632
<212>      DNA
<213>      Woodchuck hepatitis B virus

<220>
<221>      misc_signal
<222>      (1)..(632)
<223>      woodchuck hepatitis virus posttranscriptional regulatory element

```

```

<400>      7
accaggttct gttcctgtta atcaacctct ggattacaaa atttgtgaaa gattgactgg      60

```

## Sequence Listing

---

tattcttaac tatgttgctc cttttacgct atgtggatac gctgctttaa tgcctttgta	120
tcattgctatt gcttcccgta tggctttcat tttctcctcc ttgtataaat cctggttgct	180
gtctctttat gaggagtgtt ggcccgttgt caggcaacgt ggcgtggtgt gcactgtgtt	240
tgtgaagca acccccactg gttggggcat tgcaccacc tgcagctcc tttccgggac	300
tttcgcttcc cccctcccta ttgccacggc ggaactcatc gcgcctgcc ttgcccgctg	360
ctggacaggg gctcggctgt tgggcactga caattccgtg gtgttgctgg ggaagctgac	420
gtcctttcca tggctgctcg cctgtgttgc cacttgatt ctgcgggga cgtccttctg	480
ctacgtccct tcggccctca atccagcga ccttccctcc cggggcctgc tgcgggctct	540
gcggcctctt ccggtcttc gcttcgccc tcagacgagt cggatctccc tttgggcgc	600
ctccccgct gtttcgctc gggctcctcg ag	632

<210> 8

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> forward primer for amplifying neomycin resistant gene

<400> 8

gcggccgcgc gcgtcaggtg gcac

24

<210> 9

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

## Sequence Listing

---

<223> reverse primer for amplifying neomycin resistant gene

<400> 9

cgatcggacg ctcatgtgaa cgaaaactc

29

<210> 10

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> forward primer for amplifying chicken B-globin insulator

<400> 10

tcgactctag agggacag

18

<210> 11

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> reverse primer for amplifying chicken B-globin insulator

<400> 11

ctcactgact cegttcct

18

<210> 12

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> forward primer for amplifying woodchuck hepatitis virus



## Sequence Listing

posttranscriptional regulatory element

<400> 12

accaggttct gttcctgtta atcaacctc

<210> 13

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> reverse primer for amplifying woodchuck hepatitis virus  
posttranscriptional regulatory element

<400> 13

ctcgaggagc ccgaggcgaa acaggcg

27